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Abstract
Members of the ATP-binding cassette (ABC) family of drug transporter proteins translocate various
endogenous and exogenous substrates across intra- and extracellular membranes. Two specific ABC
transporters, the multidrug resistance 1/P-glycoprotein (MDR1/P-gp) and the multidrug resistance protein
2 (MRP2), serve as major hepatic transporters that mediate the biliary excretion of various organic anions
and cations along with glutathione-, glucuronate-, or sulfate-conjugates of several drug substrates.
However, very little is known about the expression of these transporters in the early infant and childhood
ages of human development. We, therefore, characterized the ontogeny of these transporters by
measuring their gene and protein expression. Furthermore, we also characterized the ontogeny of four
nuclear receptors through measurement of their gene expression. Nuclear receptors belong to a highly
conserved gene superfamily of transcriptional factors that regulate the expression of their target genes,
many of which include members of the ABC transporters. We identified four main nuclear receptors that
have been associated with the modulation of gene expression of MDR1/P-gp and MRP2 to include
pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR), and
hepatic nuclear factor 4a (HNF4alpha). Our study revealed lower gene expression of MDR1/P-gp and
MRP2 in the early infant period of development. We also identified a lower protein expression of MRP2 in
the early infant period. For the nuclear receptors, we found significantly lower expression levels for PXR
and FXR in the early periods of development. Positive correlations were established between the nuclear
receptors PXR and FXR to the ABC transporters MDR1/P-gp and MRP2. HNF4a, which has been described
as a master regulator of other nuclear receptors, was determined to be positively correlated with PXR and
CAR.
Due to the various challenges associated with conducting scientific research in newborns, infants and
children and obtaining tissue samples in this population, we wished to establish the ontogeny of the
human equivalent of the ABC transporters and nuclear receptors in a rat model. As such, we determined
the ontogeny of Mdr1a/1b, Mrp2, Pxr, Car, Fxr, and Hnf4alpha from rat liver samples in seven different
postnatal ages in order to compliment our human results with more selected spacing of age and sample
numbers in our rat samples. Similar to our human pediatric liver findings, rat liver Mdr1a/1b and Mrp2
gene expression appeared limited in the first week of life and increased thereafter. The same findings
were true for the rat P-gp and Mrp2 protein samples. The rat nuclear receptors Pxr, Car, and Fxr all
exhibited a positive correlation with both Mdr1a/1b and Mrp2 gene expression. Furthermore, Hnf4a was
also positively correlated with all three nuclear receptors.
In a subsequent experiment, we aimed to explore the functional consequences in changes in drug
transporter expression on the pharmacokinetics of their drug substrates. Ceftriaxone, a third generation
cephalosporin antibiotic frequently used in pediatric pharmacotherapy, was selected as our model
compound. The pharmacokinetics of a single intravenous dose of ceftriaxone was compared between
wild-type (WT) Wistar rats as compared to a mutant strain of Mrp2-deficient (TR-) rats. We chose the use
of TR- rats as a surrogate animal to represent the immaturity of Mrp2 early on in development as was
evident from our rat and human liver samples model. Using the TR- rat model, we reported significantly
longer elimination half-life (t1/2) (p < 0.05), undetectable amounts of drug in the feces (p < 0.05), and an
increase in the urinary excretion of unchanged drug (p < 0.001) in the TR- as compared to the WT rats.
In summary, these results demonstrate that the hepatic ABC transporters MDR1/P-gp and MRP2 are
differentially expressed during childhood maturation and suggest that the observed reduced expression
of MRP2 in human liver in early infancy may result in clinically significant differences in the disposition of
medications used in pediatric pharmacotherapy.
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ABSTRACT
Members of the ATP-binding cassette (ABC) family of drug transporter proteins
translocate various endogenous and exogenous substrates across intra- and extracellular
membranes. Two specific ABC transporters, the multidrug resistance 1/P-glycoprotein
(MDR1/P-gp) and the multidrug resistance protein 2 (MRP2), serve as major hepatic
transporters that mediate the biliary excretion of various organic anions and cations along
with glutathione-, glucuronate-, or sulfate-conjugates of several drug substrates.
However, very little is known about the expression of these transporters in the early
infant and childhood ages of human development. We, therefore, characterized the
ontogeny of these transporters by measuring their gene and protein expression.
Furthermore, we also characterized the ontogeny of four nuclear receptors through
measurement of their gene expression. Nuclear receptors belong to a highly conserved
gene superfamily of transcriptional factors that regulate the expression of their target
genes, many of which include members of the ABC transporters. We identified four
main nuclear receptors that have been associated with the modulation of gene expression
of MDR1/P-gp and MRP2 to include pregnane X receptor (PXR), constitutive androstane
receptor (CAR), farnesoid X receptor (FXR), and hepatic nuclear factor 4α (HNF4α).
Our study revealed lower gene expression of MDR1/P-gp and MRP2 in the early infant
period of development. We also identified a lower protein expression of MRP2 in the
early infant period. For the nuclear receptors, we found significantly lower expression
levels for PXR and FXR in the early periods of development. Positive correlations were
established between the nuclear receptors PXR and FXR to the ABC transporters
MDR1/P-gp and MRP2. HNF4α, which has been described as a master regulator of
other nuclear receptors, was determined to be positively correlated with PXR and CAR.
Due to the various challenges associated with conducting scientific research in
newborns, infants and children and obtaining tissue samples in this population, we
wished to establish the ontogeny of the human equivalent of the ABC transporters and
nuclear receptors in a rat model. As such, we determined the ontogeny of Mdr1a/1b,
Mrp2, Pxr, Car, Fxr, and Hnf4α from rat liver samples in seven different postnatal ages
in order to compliment our human results with more selected spacing of age and sample
numbers in our rat samples. Similar to our human pediatric liver findings, rat liver
Mdr1a/1b and Mrp2 gene expression appeared limited in the first week of life and
increased thereafter. The same findings were true for the rat P-gp and Mrp2 protein
samples. The rat nuclear receptors Pxr, Car, and Fxr all exhibited a positive correlation
with both Mdr1a/1b and Mrp2 gene expression. Furthermore, Hnf4α was also positively
correlated with all three nuclear receptors.
In a subsequent experiment, we aimed to explore the functional consequences in
changes in drug transporter expression on the pharmacokinetics of their drug substrates.
Ceftriaxone, a third generation cephalosporin antibiotic frequently used in pediatric
pharmacotherapy, was selected as our model compound. The pharmacokinetics of a
single intravenous dose of ceftriaxone was compared between wild-type (WT) Wistar rats
as compared to a mutant strain of Mrp2-deficient (TR-) rats. We chose the use of TR-
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rats as a surrogate animal to represent the immaturity of Mrp2 early on in development as
was evident from our rat and human liver samples model. Using the TR- rat model, we
reported significantly longer elimination half-life (t1/2) (p < 0.05), undetectable amounts
of drug in the feces (p < 0.05), and an increase in the urinary excretion of unchanged drug
(p < 0.001) in the TR- as compared to the WT rats.
In summary, these results demonstrate that the hepatic ABC transporters
MDR1/P-gp and MRP2 are differentially expressed during childhood maturation and
suggest that the observed reduced expression of MRP2 in human liver in early infancy
may result in clinically significant differences in the disposition of medications used in
pediatric pharmacotherapy.
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CHAPTER 1. INTRODUCTION

Developmental Pharmacology
Developmental pharmacology represents an area of pediatric research that translates
our current knowledge of normal physiologic growth and development into age
appropriate clinical pharmacotherapy. This relatively new field within pharmacologic
research grew out of necessity in the late 20th century with an emergence of reports
describing a lack of drug efficacy and/or drug related toxicity in the neonatal and
pediatric population. Standard classical approaches of using dosing guidelines based on
adult doses scaled for weight or body surface area (BSA) may lead to toxicity in the
pediatric population. This is well documented in the case of “gray baby syndrome”
where infants given adult doses of chloramphenicol scaled by body weight died of
chloramphenicol toxicity due to the inability of their liver enzymes to detoxify the drug.
Sadly, the newborns who received chloramphenicol exhibited a myriad of physical signs
and symptoms including an ashen appearance (thus termed “gray baby syndrome”),
vomiting, respiratory distress, refusal to feed, periods of cyanosis, abdominal distention,
cadiovascular collapse, and eventually death [1]. Other examples of drugs exhibiting an
increase or decreased efficacy, or worse, ineffective drug therapy and/or severe toxicity
in the pediatric population include zidovudine, acetaminophen, caffeine, digoxin,
aminoglycosides, carbamazapine, valproic acid, and phenytoin [2, 3].
The Food and Drug Administration Modernization Act of 1997 (FDAMA)
emphasizes the critical need for clinical studies and improved guidelines of drug use in
pediatrics. In particular, FDAMA allows the regulatory agency to not only mandate
labeling changes for a list of approved drugs for which additional pediatric information
may produce health benefits but also, when appropriate, to request manufacturers to
design and conduct pediatric clinical trials on new drug applications. This mandate has
led to the creation of a Pediatric Priority List, consisting of drugs with off-labeled usage
in pediatrics. The list has been updated annually to include new drug entities and remove
drugs updated with new pediatric labeling. An example of the drugs on the Pediatric
Priority List is shown in Table 1-1. A more recent law passed by Congress in 2002,
termed the Best Pharmaceuticals for Children Act (BPCA), encourages drug
manufacturers or sponsors to conduct pediatric studies for either on-patent or off-patent
drugs. In return, the manufacturer may obtain six months of additional market
exclusivity for their patented drug. Should the manufacturer decline the request from the
Food and Drug Administration regarding further pediatric studies, especially in the case
for off-patent drugs, the act then enables the Foundation for the National Institute of
Health (FNIH) to fund such studies.
In order to achieve safe and effective use of drugs in pediatrics, there must be an
understanding of the impact of the normal growth and development process (ontogeny)
on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of medications. The
fundamental pharmacokinetic processes include absorption, distribution, metabolism, and
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Table 1-1.

Example of Drugs Currently Listed on the Pediatric Priority List.

Product Name

Indication

Albuterol
Alprazolam
Ampicillin/sulbactam
Benazepril
Bumetanide
Cephalexin
Diclofenac
Dopamine
Efavirenz
Furosemide
Lithium
Methylphenidate
Metoclopramide
Omeprazole
Oxycodone
Paroxetine
Pravastatin
Rosiglitazone
Valproate
Venlafaxine

Asthma
Anxiety
Antibiotic
Hypertension
Diuresis
Antibiotic
Anti-inflammatory
Increase cardiac output
HIV infection
Diuresis
Bi-polar disorder
Attention-deficient hyperactivity disorder
Prokinetic
Gastro-esophageal reflux
Pain
Depression. Obsessive-compulsive disorder
Hypercholesterolemia
Type II diabetes
Mania. Migraine prevention. Seizures.
Depression. Generalized anxiety disorder.
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elimination (ADME) while pharmacodynamics can be described by the relationship of
the concentration at the effect site and the observed beneficial or toxic effects.
Absorptive processes that can change with maturation include factors such as
gastric pH, gastric emptying and motility, intestinal length, epidermal thickness, and even
skeletal-muscle blood flow. Distribution of drugs into a physiologic space relies heavily
on the body composition of an individual. Since distribution of small drug molecules in
the body is mainly driven by diffusion, their physicochemical properties including
molecular weight, ionization, and permeability are crucial determinants of their volume
of distribution. For example, infants in general have relatively larger extracellular (40%
total body weight) and total-body water spaces (80%) along with higher water to lipid
ratio in their adipose stores as compared to adults (20% extracellular/50% total-body
water). Thus, the apparent volumes of distribution for hydrophilic drugs in newborns
will be larger then those of adults. Another factor that can alter the volume of
distribution is protein binding. Newborns have frequently reduced plasma protein binding
as compared to adults. This results in a higher fraction of unbound drug in the plasma of
newborns. Reduced protein binding in newborns may be due to an overall decrease in
total plasma protein concentration, higher plasma free fatty acids concentration and
unconjugated bilirubin resulting in competitive displacement of acidic drugs from
albumin binding sites, and potential competitive binding from residual compounds passed
from the mother prior to birth [4].
Drug metabolizing enzymes (DMEs) are subdivided into two groups – Phase I and
Phase II. Phase I enzymes are primarily responsible for the biotransformation of a wide
array of endogenous and exogenous compounds. Phase II enzymes generally inactivate
or detoxify xenobiotics through conjugation with small molecules such as glutathione,
uridine diphosphate glucuronic acid (UDPGA), or sulfates. More recently, elimination of
xenobiotics and their metabolites by uptake and export transporters has been referred to
as Phase III of the elimination process. Pediatric drug metabolism differs greatly from
adults due to a differential maturation in drug-metabolizing enzymes prior to and after
birth. The ontogeny of Phase I enzymes, comprised of those in the cytochrome P450
(CYP450) family, has been well characterized for several members including CYP3A,
CYP2C, CYP2D, CYP2E, and CYP1A (Figure 1-1). The CYP3A enzymes account for
approximately 30% of total hepatic CYP450 content [5] and contributes to the oxidative
metabolism of approximately 50% of marketed drugs [6]. CYP3A7 has been established
as the predominant enzyme of the CYP3A family in newborns. An ontogenic switch
from CYP3A7 to CYP3A4 occurs shortly after birth whereby 3A7 rapidly declines in the
first weeks of life and 3A4 increases throughout the postnatal period [7, 8]. Though
CYP2D6 protein can be detected in the neonate liver, its activity (as assessed by
dextromethorphan metabolism) remains low (< 1% of adults) and only increases to
approximately 20% of adult enzymatic activity after 28 days of life [9, 10]. The CYP2C
subfamily accounts for approximately 20% of the total adult CYP450 content and
metabolism of current drugs on the market [5, 11]. The two predominant isoforms of the
CYP2C family include CYP2C9 and CYP2C19. At birth, CYP2C9 expression is
comparable to that of adults but CYP2C19 expression requires an additional five months
of postnatal development before reaching maximal values [12]. Expression and function
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Figure 1-1. Ontogeny of CYP450 Family of Drug Metabolizing Enzymes.
Source: Reprinted from Seminars in Fetal and Neonatal Medicine, Volume 10, Blake M.
J. et al., ‘Ontogeny of drug metabolizing enzymes in the neonate’, 123-38, 2005, with
permission from Elsevier.
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of both CYP2E1 and CYP1A1 increase with postnatal age. Furthermore, the large
variability observed for CYP2E1 and CYP1A1 expression appears to be dependent upon
xenobiotic induction or inhibition along exposure to various environmental factors [13].
Knowledge regarding the development of Phase II metabolizing enzymes including
glucuronosyltransferases (UGT), sulfotransferases (SULT), glutathione-S-transferases
(GST), and N-acetyltransferases (NAT) is incomplete. However, preliminary reports
suggest that while many of the Phase II enzymes are expressed early in development
others exhibit tissue-specific ontogenic expression [14]. Many of the Phase III
transporters belong to the ATP-binding cassette family (ABC) as well as the solute
carrier family (SLC). These transporters can facilitate the cellular uptake or extrusion of
various endogenous and exogenous compounds. Expression of these transporters appears
organ and tissue specific, however, very little is known regarding the ontogeny of these
transporters. A more detailed discussion of these various drug transporters will be
provided in the subsequently sections.
Renal elimination of xenobiotics depends on glomerular filtration rate, active
secretion and reabsorption through renal tubular transporters, as well as passive
reabsorption. At birth, glomerular filtration rate (GFR) increases dramatically with
postnatal age and approaches adult values as early as 6 months of age for a full term
infant [15, 16]. Renal secretion and reabsorption depend on various transporters
including those belonging to the ATP-binding cassette (ABC) family, organic
anion/cation transporters (OATs/OCTs), and the peptide co-transporter PEPT2, a member
of the SLC15 family [17]. Unfortunately, little information exists regarding the
maturation of these transporters in the renal tubule. Ongoing research has already
improved the identification and characterization of these renal transporters, but
ultimately, studies into their developmental processes will help clarify our understanding
of pediatric renal drug elimination.
Similar to renal transporters, ontogeny of pharmacodynamic (PD) processes has
received little attention in the literature. The phamacodynamic response is a result of the
interaction between the drug molecule and receptors and its downstream molecular
consequences including changes in ion channels, second messenger systems, and
signaling pathways results in a complex process. Much of the Food and Drug
Administration (FDA) guidance for conducting pediatric studies [18] is based upon an
underlying assumption that drug action, concentration-response rate, and clinical
outcomes in pediatric pharmacotherapy are comparable to adults. However, as in the case
of tacrolimus, the imprecision resulting from the use of a priori PK parameters from
adults in a pediatric model demonstrates the limitations of these basic assumptions [19].
Pharmacodynamic parameters including receptor concentration, affinity, and intrinsic
activity may very well demonstrate age-associated differences in their effect. Doseresponse discrepancies due to age-associated effects have been documented for warfarin
[20], cyclosporine [21], sotalol [22] and midazolam [23].
While advances in developmental pharmacology during the past decade have
certainly improved our understanding of pediatric physiology, there remains a gap in
incorporating these age-associated changes into clinical pharmacotherapy. Furthermore,
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the maturation of key PK parameters including several Phase II drug metabolizing
enzymes, Phase III transporters, and various PD parameters such as cellular receptors and
signaling pathways still warrant further investigation.
Hepatic Drug Disposition
For most small molecule drugs, overall drug elimination occurs through two main
components; namely, clearance via the renal route (CLR) and clearance via hepatic
metabolism and transport (CLH). As described previously, efficient and effective
biotransformation and inactivation/detoxification of xenobiotics starts with Phase I and
Phase II drug metabolizing enzymes. Furthermore, elimination of xenobiotics and their
metabolites through liver transporters into the bile is part of Phase III of the elimination
process. Because of the overlap in their substrate specificity, tissue distribution, and gene
regulation between several drug metabolizing enzymes and transporters, Phase I/II and
Phase III processes appear to work synergistically to decrease the oral bioavailability and
increase the renal and biliary excretion of xenobiotics [24-26].
It is well established that genetic polymorphisms and environmental factors can
influence an individual’s expression and function of DMEs [27]. However, recent studies
suggest that developmental changes in DMEs can also contribute to the variability
observed for drug metabolism. Detailed reviews in recent years on the development of
Phase I and Phase II enzymes provide detailed insight into the differences observed
between pediatric versus adult pharmacokinetics [3, 13-15, 28]. However, knowledge
regarding drug transporter ontogeny is currently very limited.
Hepatic Transporters
As mentioned previously, Phase III transporters are comprised of those belonging in
the ATP-binding cassette family (ABC) as well as the solute carrier family (SLC).
Hepatic transporters are an essential component in the overall hepatic clearance and
hepatobiliary elimination. A multitude of hepatic transporters align both the apical
(canalicular) and basolateral (sinusoidal) membranes of the hepatocyte (Figure 1-2).
Transporters expressed in the basolateral membrane mediate the uptake of various
organic anions and cations from the blood into the liver [29, 30]. Transporters in the
canalicular membrane belong to the ABC family and mediate the transport of various
organic anions and cations along with glutathione-, glucuronate-, or sulfate-conjugates of
several drug substrates into the bile. The focus of the current dissertation will focus on
these apical transporters, specifically MDR1/P-gp (ABCB1) and MRP2 (ABCB2), as
these are the main transporters which mediate the hepatobiliary elimination of a number
of drug substrates (for simplicity, only the common transporter name will be used).
However, the role of the uptake transporters in hepatic clearance should not be
undermined and will be considered in future investigations.
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Figure 1-2. Select Drug Transporters in Human Hepatocytes.
MDR1/P-gp (ABCB1), multidrug resistance 1; MRP1 (ABCC1), multidrug resistance
protein 1; MRP2 (ABCC2), multidrug resistance protein 2; MRP3 (ABCC3), multidrug
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The ATP-binding cassette (ABC) superfamily of transporters consists of seven
subfamilies of highly conserved proteins that mediate the unidirectional transport of
various endogenous as well as exogenous compounds. MDR1/P-gp was originally
identified in 1976 as a 170 kDa cell surface glycoprotein displaying drug resistance
properties in cancer cells [31]. Several years later, this multidrug transporter was found
to actively extrude a large number of diverse compounds including natural products,
hydrophobic amphipathic compounds, as well as cytotoxic drugs used in anticancer
therapy [32]. In humans, P-gp is encoded by the MDR1 gene. However, in rodents, P-gp
is the product of two gene isoforms – Mdr1a and Mdr1b. The sequence homology along
with domain organization of all ABC transporters is well conserved. ABC transporters
characteristically have 12 transmembrane regions organized into two membrane spanning
domains (MSDs). Each MSD is associated with a nucleotide-binding domain (NBD)
located on the cytoplasmic side of the membrane (Figure 1-3 and Figure 1-4) [33, 34].
The α-helices of the MSDs form pore-like structures through which different substrates
on the intracellular side can be extruded across the lipid bilayer. Conformational changes
within MSDs due to substrate binding are believed to induce an open or closed state of
these transporters [35, 36]. Adenosine triphosphate (ATP) associated with the binding
domains provides the energy required for active transport of substrates against the
concentration gradient. P-gp is highly expressed in several organs including the brush
border membrane of enterocytes, the canalicular surface of hepatocytes, the apical
surface of proximal tubules in the kidney, and the endothelial cells of the blood brain
barrier [37, 38]. Localization of P-gp is particularly conducive for its role in extruding
xenobiotics or toxins thereby protecting against cellular toxicity.
MRP2, initially named the canalicular multi-specific organic anion transporter
(cMOAT), was discovered as the defective transporter in the human Dubin-Johnson
syndrome as well as the naturally occurring mutant strains of the Eisai
hyperbilirubinemic (EHBR) and transport deficient (TR-) rats. MRP2 is encoded by the
ABCC2 gene and has a molecular weight of approximately 190 kDa. Unlike P-gp, the
structure of MRP2 contains an extra membrane spanning domain at the NH2-termus
which terminates in the extracytosolic region (Figure 1-3B) [39, 40]. MRP2 is highly
expressed in the gut, liver, and kidney and shares many of the same substrates as P-gp
[41]. MRP2 plays an important role in the hepatobiliary transport of a range of
conjugated and unconjugated anionic compounds as well as bile acids and bilirubin. Due
to its function in the transport of a gamut of glucuronidated drug substrates, it is no
surprise that MRP2 co-localizes with various Phase II metabolizing enzymes.
Furthermore, MRP2 mediated transport of xenobiotics often depends on co-transport with
reduced glutathione (GSH) [42].
Similar to Phase I and Phase II enzymes, hepatic transporters are subject to genetic
polymorphisms drug-induced inhibition, and drug- and disease-induced alterations of
expression levels. These interactions and alterations may profoundly influence the fate of
drugs. An example of a transporter based drug-drug interaction involves fexofenadine
and erythromycin. Fexofenadine, a histamine 1 (H1)-selective antagonist, does not
undergo significant biotransformation in humans with 95% of the dose excreted in either
urine or bile [43]. Co-administration of fexofenadine with erythromycin increases the
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A

B

Figure 1-3. Predicted Secondary Structures of P-gp (A) and MRP2 (B).
MSD, membrane spanning domain; NBD, nucleotide binding domain; CL, cytoplasmic
loop. Source: Reprinted from Toxicology and Applied Pharmacology, Volume 204,
Leslie E.M. et al., ‘Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2,
and BCRP (ABCG2) in tissue defense’, 216-237, 2005, with permission from Elsevier.

9

MSD1

MSD2

Extracellular

Intracellular

NBD1

NBD2

ATP

ADP + Pi
Figure 1-4. Graphic Representation of P-gp.
Represented is a single P-gp transporter with two membrane spanning domains (MSDs)
each associated with six transmembrane regions. Associated with each MSD is a
nucleotide binding domain (NBD). Grey arrows trace the path of substrates.
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steady state plasma levels of fexofenadine by 109% [44]. A study using isolated perfused
rat liver with fexofenadine and erythromycin concludes that erythromycin inhibits the
biliary excretion of fexofenadine thus contributing to its increase in plasma concentration
[45]. Another documented transporter based drug-drug interaction occurs between
digoxin and quinidine. Quinidine inhibits biliary excretion of digoxin as mediated
through P-gp by as much as 42% [46].
As more transporter associated drug interactions emerge in the literature,
knowledge about the changes which occur during transporter development become
increasingly important. While the ontogeny of hepatic Phase I and Phase II clearance
mechanisms have been well documented [16], little is known regarding the development
of drug transporters and its potential impact on the pharmacokinetic and
pharmacodynamic profile of medications. One of the most dramatic examples of P-gp
associated drug toxicity involves the use of loperamide, a potent opioid agent often used
as an antidiarrheal agent. Central nervous system (CNS) toxicity by loperamide results in
respiratory depression; however, at the recommended doses, loperamide entry into the
CNS is prevented by P-gp at the blood brain barrier. Despite its apparent safety, case
reports of loperamide induced respiratory depression in infants have been described in the
literature [47, 48] and loperamide is contraindicated for children under two year of age.
The question whether this is directly due to a lower expression of P-gp in children
younger than two years remains to be answered. Another example of a potential
transporter related drug toxicity involves ceftriaxone and MRP2. Ceftriaxone is a third
generation cephalosporin antibiotics often used in the pediatric population to treat lower
respiratory infections or acute otitis media. Approximately 33% of the drug is eliminated
unchanged in the bile through MRP2 [49, 50]. There are several clinical reports of
ceftriaxone related biliary sludge or pseudolithiasis in the pediatric population [51, 52].
This is secondary to the high concentration of ceftriaxone in the liver which forms an
insoluble salt with calcium in the bile [53]. In fact, in cases where high doses of
ceftriaxone are given, the risk of ceftriaxone induced cholestasis drastically increases
[54]. Little is known regarding the development of MRP2 in the human liver. Immature
or lower expression of MRP2 in the liver in the early years of life may lead to an
accumulation of ceftriaxone in the hepatocyte and thus, increase the risk of cholestasis.
However, further studies are needed in order to elucidate the development of MRP2 in
human pediatric livers and confirm the mechanisms underlying these adverse events
caused by administration of ceftriaxone in children.
Nuclear Receptors – PXR, CAR, FXR, HNF4α
Like the ABC transporters, nuclear receptors (NRs) also comprise a highly
conserved superfamily of genes. Instead of encoding for drug transporters though, NRs
transcribe into various transcriptional factors which regulate the expression of their target
genes. Functionally, constitutive and inducible NRs can modulate the expression of
several phase I and II drug metabolizing enzymes as well as drug transporters when
activated by endogenous and exogenous compounds including hormones and drug
molecules [55, 56]. The well conserved structure of NRs includes a variable modulator
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domain known as an activation function 1 (AF1) at the N-terminus followed by the DNAbinding domain (DBD) containing two well conserved zinc fingers specific to NRs.
DBD links the receptor to the promoter regions of its target genes termed either hormone
response elements (HREs) or xenobiotic response elements (XREs). Located on the Cterminus are the ligand binding domain (LBD) as well the activation function 2 (AF2).
As the name suggests, the LBD serves as the binding site for specific ligands. Upon
ligand binding, LBD undergoes a conformational change resulting in a transcriptionally
active state prepared for recruitment of coactivators by activation function 2 (AF2)
(Figure 1-5). Based on their classification, NRs can either bind to their target sequences
as a homodimer, heterodimer, or a monomer [56].
Nuclear receptors that target expression of genes which encode for P-gp and MRP2
include the pregnane X receptor (PXR/NR1I2), the constitutive androstane receptor
(CAR/NR1I3), the farnesoid X receptor (FXR/NR1H4), and the hepatic nuclear factor
4α (HNF4α) [57]. PXR and CAR have been implicated in the coordinate induction of
phase I and II drug metabolizing enzymes and drug transporters [58]. FXR is a bile acid
receptor responsible for the regulation of bile acid synthesis and enterohepatic
recirculation [59]. HNF4α, a constitutively expressed NR, is crucial for liver
development and differentiation and also appears to be a key regulator for various drug
disposition gene expression [57].
Central Hypothesis and Specific Aims
Hepatic drug clearance involves a concerted process involving drug metabolizing
enzymes and drug transporters. While much effort has been placed in understanding the
ontogeny of drug metabolizing enzymes (Phase I and Phase II), there remains a void in
our knowledge into the developmental process of drug transporters. Hepatic export
transporters of particular relevance for the elimination of clinically used drugs into the
bile include MDR1/P-gp and MRP2. We hypothesized that in pediatric livers, MDR1/Pgp and MRP2 mRNA and protein expression would be significantly lower early in
development (infancy) as compared to older ages (childhood and adulthood). We
hypothesized that these expression differences would have functional consequences that
affect the in vivo pharmacokinetics of drugs which are substrates for these transporters.
Because nuclear receptors including PXR, CAR, FXR, and HNF4α regulate the
expression of MDR1 and MRP2, we hypothesized these nuclear receptor would be
correlated with MDR1/P-gp and MRP2 expression and would also exhibit significantly
lower mRNA expression in the early period of development.
In specific aim 1 (Chapter 2), we characterized the ontogeny of hepatic drug
transporters (MDR1/P-gp and MRP2) and nuclear receptors (PXR, CAR, FXR, and
HNF4α in human pediatric liver samples. We hypothesized that there would be lower
hepatic drug transporter and nuclear receptor expression in the early infant period of
development as compared to the older childhood ages.
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Figure 1-5. Basic Structure of Nuclear Receptors.
AF, activation function; DBD, DNA-binding domain; LBD, ligand binding domain.
Reprinted with permission. Wang, H. and E.L. LeCluyse. “Role of orphan nuclear receptors in the regulation of drug-metabolising
enzymes.” Clin Pharmacokinet, 2003. 42(15): p. 1331-57.
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In specific aim 2 (Chapter 3), we defined the ontogeny of hepatic drug transporters
(Mdr1a, Mdr1b, and Mrp2) and nuclear receptors (Pxr, Car, Fxr, and Hnf4α) in SpragueDawley rats in order to better pinpoint the age-specific changes in drug transporter
expression hypothesized to occur in newborns and infants. We investigated seven
predetermined ages ranging from newborn to adults. We hypothesized that in these rats,
there would be lower hepatic drug transporters and nuclear receptors expression early on
during development as compared to the older ages.
In specific aim 3 (Chapter 4), we explored the functional consequences and
potential clinical implications of low transporter expression as postulated for newborns
and infants and determined the effect of MRP2 deficiency on the in vivo
pharmacokinetics of ceftriaxone, a Mrp2 substrate frequently used in pediatric
pharmacotherapy, in a animal model using wild-type (WT) and Mrp2-deficient (TR-)
rats. We hypothesized that in the TR- rats, there would be a decrease in overall clearance
(CLT), longer half-life (t1/2), higher area under the curve (AUC), and no biliary excretion
(as determined by fecal drug recovery) as compared to the WT rats.
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CHAPTER 2. AGE-ASSOCIATED EXPRESSION OF HEPATIC ABC DRUG
TRANSPORTERS AND NUCLEAR RECEPTORS IN HUMAN PEDIATRIC
LIVER

Introduction
As discussed in Chapter 1, maturational changes in the physiology of organs
involved in drug disposition can translate into profound differences observed in the
pharmacokinetic and pharmacodynamic properties of various therapeutic agents often
used in pediatric pharmacotherapy. Developmental changes in the gastrointestinal tract,
protein binding, drug metabolizing enzymes and drug transporters, and renal filtration are
just some examples of factors that can impact the absorption, distribution, metabolism,
and elimination (ADME) of drug molecules.
The 1962 Kefauver-Harris amendments to the Food, Drug, and Cosmetics Act
(FD&C) mandated that prior to approval marketed drugs must have documented safety
and efficacy for use in humans. However, pharmaceutical manufacturers often excluded
children during the clinical trials and labeled the use of such medications only in adults
with a disclaimer that safety and efficacy had not been established in children.
Unfortunately, deviations in the pharmacokinetic parameters of therapeutic agents often
used as “off-label” medications in pediatric pharmacotherapy can lead to adverse risks
such as underdosing, overdosing, and unanticipated adverse events. Dr. Harry Shirkey,
then chair of the American Academy of Pediatrics Committee on Drugs in 1968, called
attention to the exclusion of children and coined the term “therapeutic orphan” [60].
The complexity of physiological and pathophysiological processes which occur
during the maturational process certainly adds a level of intricacy in studies involving the
pediatric population. The ontogeny of drug metabolizing enzymes and its contribution
towards differences seen in pediatric drug biotransformation have been widely studied
and reviewed [2, 3, 13, 61]. However, studies regarding the ontogeny of drug
transporters are still limited. What is known about the development of drug transporters
stem from mainly rodent models [61-65]. Furthermore, the animal data mostly focus on
the development of transporters in rodent brain, intestine, and kidney rather than liver
tissue [61-63, 66]. There are, however, a few human studies on the ontogeny of drug
transporters using post-mortem fetal samples [65, 67]. Currently, there are no published
studies on the development of human hepatic drug transporters during the early postnatal
into childhood ages.
In general, most of the rodent studies suggest the presence of an age associated
difference of transporter expression in various organs. One of the most studied ABC
transporters thus far, due to its ability to extrude drug substrates from cells, has been
MDR1/P-gp. Using a mouse model, Watchko [66] has reported limited intestinal and
brain P-gp expression at birth (approximately 20% of adult), but levels dramatically
increased throughout maturation [66]. On the flipside, hepatic and renal levels of P-gp in
neonatal mice and throughout development have been quantified at levels comparable to
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adult values [62]. In rats, Mdr1a and Mdr1b have also been reported to exhibit age
associated differences at the mRNA and protein level in the liver, kidney, brain, heart and
lung. Specifically, transcript level ranged two to three folds lower at birth with levels
increasing throughout maturation reaching maximal expression by postnatal day 60 [63].
In early gestation (14-20 weeks) human fetal liver samples, van Kalken [65] was able to
detect P-gp in the bile canaliculi by as early as 14 weeks through immunostaining. No
differences in staining intensity were observed between the specimens between the
different fetal stages [65].
Another transporter in the ABC family with a significant role in hepatobiliary
elimination of drug substrates is MRP2. Ontogeny of Mrp2 mRNA expression has been
explored in rodent models in recent years. The results showed an approximate 50%
increase in Mrp2 mRNA expression from birth through postnatal day 60 in the rat liver
and kidney [63]. A separate study quantified the postnatal Mrp2 protein expression level
in rat liver and concluded that at birth, neonate expression of Mrp2 approximated 70% of
adult values, eventually surpassed the adult values within a month and a half, but
eventually leveled to adult values within three months [68]. One study noted
approximately 50% Mrp2 mRNA expression in one day old rat liver tissue which
dramatically increased to adult levels in one to three weeks. In the same samples, Mrp2
protein levels approximated < 20 % of adults in the same group and increased gradually
to those of adults values by 4 weeks of age [69]. For humans, Chen [67] showed a 50%
lower MRP2 genetic expression level in ten human fetal liver samples between 14 – 20
weeks as compare to adult liver samples [67].
Nuclear receptors comprise transcriptional factors which regulate the expression of
their target genes, several of which include drug metabolizing enzymes and drug
transporters [70]. While limited reports of drug transporter ontogeny in animal models
and human fetal liver samples are slowly surfacing, studies on the developmental
expression of nuclear receptors are even scarcer. PXR and CAR, both members of the
NR1 family, are key regulators of genes involved in the metabolism and transport of most
xenobiotics, including CYP3A and P-gp/MDR1 [58, 71, 72]. Another member of the
NR1 family, FXR, is a bile acid sensor responsible for regulation of bile acid synthesis
and enterohepatic recirculation [56, 73, 74]. All three nuclear receptors are associated
with the regulation of MRP2 [72]. Another hepatic nuclear receptor, HNF4α, has been
reported as a master regulator of PXR [75] and CAR [76]. Vyhlidal [77], in a recent
study with limited postmortem pediatric liver samples (n = 20; ages 4 days to 18 years),
reported an age association in mRNA expression of PXR and CAR. Furthermore,
expression of PXR and CAR were limited in the first six months of life, but increased
several folds after six months of age. In the same study, the authors also quantified
mRNA expression of HNF4α and showed that HNF4α was positively correlated with
both PXR and CAR expression [77].
While the rodent studies provide us some information regarding the developmental
expression of ABC transporters Mdr1/P-gp and Mrp2 in various tissues, studies regarding
the development of such transporters and nuclear receptors in humans are rare due to the
limited availability of human pediatric liver samples. While the small number of
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available reports based on human fetal and postmortem pediatric liver samples provide a
glimpse into some pre- and postnatal transporter and nuclear receptor expression, there
still lacks information during other phases of development such as during the newborn
and early childhood periods.
The overall object of the present study was to characterize the ontogeny of ABC
transporters MDR1 and MRP2 as well as the nuclear receptors PXR, CAR, FXR, and
HNF4α in human pediatric liver samples ranging from immediately after birth through
twelve years of age. Potential age associated changes in hepatobiliary transporters
MDR1/P-gp and MRP2 may result in significant differences in the biliary clearance of
medications used in pediatric pharmacotherapy. Knowledge regarding the impact of such
changes in transporter expression during the newborn and early childhood periods on
pharmacokinetic parameters can contribute to more age-appropriate dosing and thus
better safety and efficacy profiles especially for those medications with limited or no
labeling for pediatric use.
Materials and Methods
Sample Acquisition
Human pediatric liver tissues were acquired from two main sources – St. Jude
Children’s Research Hospital (SJCRH, Memphis, TN) and the Medical College of
Wisconsin (MCW, Milwaukee, WI). The samples from SJCRH (n = 62) originated from
the Liver Tissue Procurement and Distribution System (University of Pittsburgh,
Pittsburgh, PA, funded by National Institutes of Health Contract N01-DK-9-2310) and
from the Cooperative Human Tissue Network (University of Alabama, Birmingham, AL,
funded by the National Cancer Institute). Samples from MCW (n = 67) originated from
the Brain and Tissue Bank for Developmental Disorders, University of Baltimore and
University of Miami (National Institute of Child Health and Human Development
contract N01-DK-8-3284). All samples were collected from donors less than twelve
years of age. The SJCRH samples were obtained from living donors either through
biopsy or within one hour of cross-clamping in the case of organ donors. Harvested
tissue was immediately flash frozen in transplant solution. Demographic information on
the donor population and health status is provided in Table 2-1. All SJCRH samples
were used for the mRNA expression analysis and a subset (n = 45) was used for the
protein analysis. The unmatched sample numbers between mRNA and protein
expression analysis was due to limitations in tissue availability.
Unlike the SJCRH samples, all MCW samples were obtained from deceased
donors. Due to the degradation of mRNA during the period from time of death to sample
collection – defined as the post-mortem interval (PMI), the postmortem samples were
only used for P-gp and MRP2 protein analysis. The postmortem samples from donors
with disease processes that could potentially involve liver damage were excluded from
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Table 2-1.
Donor Demographics for Human Pediatric Liver Samples Provided by St.
Jude Children’s Research Hospital (SJCRH).
N

Age (yrs)
Mean ± SD

Age Group
A (< 0.7 Y)
B (0.7 - < 3 Y)
C (3 - < 6 Y)
D (6 - 12 Y)

9
19
12
22

0.53±0.18
1.69±0.45
3.83±0.83
8.38±2.04

Gender
M
F
Unknown

29
22
11

Race
Caucasian
Black
Others
Unknown

35
7
6
14

Disease status
Normal
Cirrhosis
Fibrosis
Acute Hepatitis
Necrosis

36
10
10
4
2
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the study. Demographic information for the MCW samples is provided in Table 2-2.
The combined patient demographics from SJCRH and MCW samples used for protein
expression analysis are presented in Error! Reference source not found..
Total RNA Isolation and cDNA Synthesis
Total ribonucleic acid (RNA) from human pediatric liver samples were isolated
using the phenol:chloroform method using the Promega RNAgents® Total RNA
Isolation Kit (Promega, Madison WI) according to the manufacturer’s protocol. Frozen
liver tissue (approximately 0.3 g) was added to 600 µL of denaturing solution per
protocol and subjected to homogenization until no fragments of tissue were visible. To
each homogenate, 60 µL of 2M sodium acetate (pH 4.0) was added and mixed
thoroughly by inversion. 600 µL of phenol:chloroform:isoamyl alcohol was
subsequently added to the mixture and mixed by inversion 3 – 5 times followed by
vigorously shaking for 10 seconds. The samples were then placed on ice for 15 minutes.
Thereafter, the samples were subjected to centrifugation at 10,000 g for 20 minutes at 4ºC
in order to separate the organic and aqueous phases. The top aqueous phase containing
RNA was carefully separated to a fresh vial and an equal volume of isopropanol was
added to each sample. RNA was pelleted by centrifugation at 10,000 g for 15 minutes
after alcohol precipitation for 30 minutes at -20ºC. The RNA pellet was then washed
with 1.0 mL of 75% ethanol, and the pellet was again collected by centrifugation at
10,000 g for 15 minutes. The pellet was air-dried after discarding the supernatant and
evaporating the residual ethanol. Each RNA pellet was re-dissolved in 10 – 50 µL of
nuclease-free water depending on the pellet size. RNA concentrations were determined
by measuring its ultraviolet absorbance (A) at 260 nm and 280 nm, respectively, whereby
1 absorbance unit (A260) = 40 µg of RNA/mL. The purity of the RNA isolate was
estimated by comparing the ratio for A260/A280. Samples were considered to be pure
total RNA with only minor protein contamination if the ratio of A260/A280 calculated
between 1.7 and 2.0. Integrity of each RNA sample was assessed by agarose gel
electrophoresis comparison of intact ribosomal 18S and 28S bands. The ratio between
28S to 18S band intensity ranged approximately around 2 – an indication that no gross
degradation of RNA had occurred during processing. Only samples with high purity and
integrity were further processed for first strand cDNA synthesis.
First strand complementary deoxyribonucleic acid (cDNA) synthesis was
performed by using the Superscript III kit (Invitrogen, Carlsbad, CA) on an Eppendorf®
Mastercycler™ (Westbury, NY). Oligo deoxyribose thymidine (dT) was used as the
primer for messenger RNA (mRNA) first-strand synthesis. An aliquot totaling 1 µg of
total RNA was mixed with 1 µL of 10 mM deoxyribonucleotide triphosphate (dNTP) mix
and 1 µL of 0.5 µg/µL Oligo(dT)12-18. The total mixture was then brought to 10 µL
with the addition of diethylpyrocarbonate-treated (DEPC) water. The mixture was
incubated at 65ºC for 5 minutes on a heating block, then immediately placed on ice for at
least one minute. A mixture of 2 µL of 10x reverse transcriptase (RT) buffer, 4 µL of 25
mM magnesium chloride (MgCl2), 2 µL of 0.1 M dithiothreitol (DTT), 1 µL of
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Table 2-2.
Donor Demographics for Human Pediatric Liver Samples Provided by
Medical College of Wisconsin (MCW).

N

Age (yrs)
Mean ± SD

PMI (hrs)
Mean ± SD

Age Group
A (<0.7 Y)
B (0.7 - < 3 Y)
C (3 - < 6 Y)
D (6 - 12 Y)

42
3
7
16

0.23±0.15
2.24±0.32
4.22±0.96
9.20±1.55

18.1±8.21
15.67±2.31
17.43±9.43
21±7.28

Gender
M
F
Unknown

45
23
0

Race
Caucasian
Black
Others
Unknown

42
22
3
1

PMI, post-mortem interval.
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Table 2-3.
Combined Patient Demographics for Human Pediatric Liver Samples for
Protein Analysis.

N

Age (Yrs)
Mean ± SD

Age Group
A (< 0.7 yrs)
B (0.7 - < 3Y)
C (3 - < 6 Y)
D (6 - 12Y)

48
15
16
33

0.26 ± 0.17
1.64 ± 0.60
3.97 ± 0.89
9.0 ± 1.75

Donor Status
living
deceased

45
67

Gender
M
F
UNK

61
44
7

Race
Caucasian
Black
Others
Unknown

68
28
7
9
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RNAseOUT™ recombinant RNase inhibitor, and 1 µL of SuperScript™ III reverse
transcriptase were added to each reaction vial. The mixture was then incubated for 50ºC
for 50 minutes and the reaction was terminated by increasing the temperature to 85ºC for
5 minutes. The residual RNA was removed by adding 1 µL of RNAse H and incubating
at 37ºC for 20 minutes. cDNA was stored at -20ºC until real-time RT-PCR was
performed.
Real Time RT-PCR
Primers pairs and TaqMan probes for P-gp/MDR1, MRP2, PXR, CAR, FXR, and
HNF4α (TaqMan® Assay-on-Demand™ Products) as well as the constitutively
expressed reference gene cyclophilin A (TaqMan® Pre-Developed Assay Reagents for
Gene Expression) were obtained from Applied Biosystems (Foster City, CA). All
targeted ABC transporter and nuclear receptor probes were labeled with 6carboxyfluorescein (FAM)-dye while the cyclophilin A probe was labeled with VIC™dye. All of the probes were quenched by 6-carboxytetramethylrohodamine (TAMRA) on
the 3’ end. Target gene probe sequences are summarized in Table 2-4. In a 96-well
reaction plate, 2.5 µL of 20X TaqMan Probe, 22.5 µL of human pediatric liver cDNA,
and 25 µL of 2 X TaqMan Universal PCR Master Mix were added. The reaction was
performed in duplicate for each sample. Real time reverse transcriptase-polymerase
chain reaction (RT-PCR) was performed using the ABI Prism® Sequence Detection
System 7000 (Applied Biosystems, Foster City, CA) using the default PCR thermal
cycling conditions consisting of an initial TaqMan Universal PCR Master Mix activation
at 50°C for 2 min, followed by an initial denaturation step at 95°C for 10 min, then 40
cycles of 95°C for 15 sec and 60°C for 1 minute.
Relative mRNA quantification was achieved through the standard curve or Ct (cycle
threshold for target or endogenous control gene amplification) slope method. The
average Ct value was calculated from replicates of each sample using the ABI Sequence
Detection System SDS software (Applied Biosystems, Foster City, CA). MRP1, MRP2,
PXR, CAR, FXR, HNF4A, and cyclophilin A standard curves were prepared from serial
dilutions of cDNA from a HepG2 cell line. Cyclophilin A (Cyc) was validated as the
most stably transcribed reference gene across all age groups. Dilutions included 1, 2, 4,
8, and 20 fold initial cDNA concentration (C0). A plot of Ct, the point at which the
amplification plot cross the threshold cycle value, vs. C0 was then constructed (Figure
2-1) as described by the assay manufacturer [78]. The threshold value was predetermined
as 3 times the average baseline cycle value calculated from cycles 6 – 15. The log
concentration of the unknown samples was then calculated by linear regression from the
standard curve. The absolute concentration was then determined by taking its antilog
value. The expression level of each target gene was then calculated relative to the
reference gene, cyclophilin A.
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Table 2-4.

Primer Sequence for Target Gene-Specific 5’-(FAM)-Labeled TaqMan® Assay-on-Demand™ Human Probes.

Gene
Symbol

Alternative
name

ABCB1
ABCC2
NR1I2
NR1I3
NR1H4
HNF4A

P-gp/MDR1
MRP2
PXR
CAR
FXR
HNF4A

Probe 5'-3'

NCBI Gene
Reference

Target
Exons

AGGTACCATACAGAAACTCTTTGAG
ACCTCCAACAGGTGGCTTGCAATTC
TACTTCAGGGACTTGCCCATCGAGG
GCCCCGGGATCGGTTTCTGTATGCG
ACAAAAAAGCTACCAGGATTTCAGA
AAGGAAGCCGTCCAGAATGAGCGGG

NM_000927
NM_000392
NM_033013.1
NM_005122.2
NM_005123.1
NM_178849.1

23
25
5
6
8
3

23

34

MDR1
MRP2
PXR
CAR
FXR
HNF4A

32

Ct

30

28

26

24

22
-1.4

-1.2

-1.0

-0.8

-0.6

-0.4

-0.2

0.0

Log Co

Figure 2-1. Calibration Curve for MDR1, MRP2, PXR, CAR, FXR, and HNF4α.
All targeted genes calibration curves have slopes of approximately -3.3, indicating an
amplification efficiency of close to 1 within the linear range. Ct, cycle threshold; C0,
initial cDNA concentration
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Tissue Membrane Protein Isolation
Liver tissue membrane protein for all human pediatric samples acquired from St.
Jude Liver Bank was extracted by the ultracentrifugation method. Briefly, approximately
2 grams of frozen liver tissue, after quick thawing in a 37ºC water bath, was
homogenized in 10 mL of homogenization buffer consisting of 0.1 M Tris pH 7.4, 0.1 M
potassium chloride (KCL), 0.02 mM butylated hydroxytoluene (BHT), and 1 mM
ethylenediamine tetraacetic acid (EDTA). The tissue was further homogenized with a
Teflon pestle at 800 rpm. The homogenate was centrifuged at 12,000 g for 15 min at
4°C. The supernatant was discarded and the remaining pellet consisting of membrane
proteins was resuspended in 5 mL of membrane storage buffer consisting of 20%
glycerol, 1 mM DTT, 0.02 mM BHT, and 0.1 potassium phosphate (KPO4) pH 7.25.
Aliquots of the membrane protein were prepared and stored in -70°C freezer until further
processing.
All membrane protein for samples received from the Medical College of Wisconsin
were extracted by Calbiochem® ProteoExtract® Native Membrane Protein Extraction
Kit (M-PEK). Briefly, approximately 50 mg of liver tissue was homogenized in 2 mL of
Extraction Buffer I and incubated for 10 minutes at 4°C under gentle agitation on a rotary
shaker. The homogenate was centrifuged for 15 minutes at 16,000 g and 4°C. The
supernatant was discarded and the pellet resuspended in 1 mL of Extraction Buffer II.
The cell pellet was then incubated for 30 minutes at 4°C again under gentle agitation on a
rotary shaker. The cell suspension was centrifuged a second time at 16,000 x g and 4 °C
for 15 minutes. The resulting supernatant enriched in membrane proteins was then
transferred to a fresh tube and stored in aliquots at -70°C until further processing.
Protein quantification was determined through the Bradford assay [79] using bovine
serum albumin (BSA; Sigma-Aldrich) as the standard. Using a 96 well plate, stock BSA
solution (0.2 mg/mL) was diluted to a final concentration ranging from 0 – 30 µg/mL
with deionized water (dH20) in the standard wells. In the sample wells, 1 µL of
membrane protein from each pediatric liver sample was diluted in 199 µl of dH20. 50 µL
of Protein Assay Dye Reagent Concentrate (Bio-Rad; complete information) was added
to each well and mixed thoroughly. All protein standards and unknown samples were
repeated in triplicates. The plate was incubated for 5 minutes at room temperature and
the protein absorbance was read on a microplate reader at 595 nm. A standard curve
using the standard BSA absorbance (A) versus concentration was constructed. All
unknown protein concentrations were subsequently calculated by linear regression. 20
µg of membrane protein from each liver sample was used for protein quantification.
SDS-PAGE/Western Blotting
To 20 µg of pediatric liver membrane protein, 2.5 mL of NuPAGE® LDS Sample
Preparation Buffer (Invitrogen, Carlsbad, CA) was added. The samples were
fractionated via sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
using NuPAGE® 4 – 12 % Bis-Tris Polyacrylamide Gel with 1X NuPAGE® MOPS
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Running buffer at 200 V for 1 hour. On each gel, we also included a MultiMark® MultiColored Protein Standard (Invitrogen, Carlsbad, CA) as well as positive controls for both
MDR1/P-gp and MRP2. Human P-gp membrane preparation (Human PGP membranes)
and MRP2 membrane preparations (Human MRP2 membranes) were purchased from BD
Gentest™ (Woburn, MA) and served as positive controls. The separated proteins were
transferred overnight onto an Invitrolon™ Polyvinylidene fluoride (PVDF) 0.2 µm
membrane at 30 V using NuPAGE® 1X Transfer Buffer with 10% methanol.
Nonspecific binding sites on the PVDF membrane were blocked using 5% nonfat
dried milk in phosphate buffered saline (PBS) with 0.1% Tween (T) for one hour at room
temperature. The membrane was then incubated with the primary monoclonal antibody
to P-gp (C219) (Alexis Biochemicals, San Diego, CA) diluted 1:100 fold, MRP2 (M2III6) (Alexis Biochemical, San Diego, CA) diluted 1:200 fold, or glyceraldehyde 3phosphate dehydrogenase (GAPDH, Sigma-Aldrich, St. Louis, MO) diluted 1:10000 fold
in 5% nonfat dried milk in PBS with 0.1 % Tween (PBST) for 2 hours at room
temperature. After discarding the primary antibody, the membrane was washed 3 times
with PBST each time for 5 minutes. The membrane was then incubated for one hour
with the secondary antibody, horseradish peroxidase-conjugated (HRP) Anti-Mouse IgG
(Cell Signaling Technology, Danvers, MA), diluted in 5% nonfat dried milk in PBST
either 1:5000 fold when probing P-gp and MRP2, or 1:10000 fold when probing for
GAPDH. GAPDH was chosen as the reference protein for the relative protein
quantification since it was more stably expressed as compared to cyclophilin A. After 3 –
5 minute washings with PBST, the blots were then incubated with enhanced
chemiluminescence ECL plus™ (GE Healthcare, Piscataway, NJ) for 5 minutes, and
developed on Kodak® Biomax™ XAR autoradiography film (Sigma-Aldrich, St. Louis,
MO) after 1 minute and 3 minute exposure times. Protein band density was quantified
using ImageJ [80] after digitizing the image using a flatbed scanner.
Statistical Analysis
All statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL).
During real time PCR, an amplification plot, reported as ∆Rn vs. Ct, was generated for
each sample (Figure 2-2). ∆Rn represented the fluorescence emission intensity of the
reporter minus the threshold Rn. Threshold Rn was determined from the pre-set baseline.
The Ct value for each sample was then used to back calculate an initial input amount by
using the equation derived from the calibration curve regression line. All data were backlog transformed in order to achieve homoscedasticity, and target gene values were then
normalized to the endogenous control cyclophilin A. In order to achieve adequate power
for statistical analysis, the liver samples were divided into four different age groups (A –
D). Group A included infants less than 8 months of age (<0.7years), group B represented
infants from 8 months to 3 years of age (0.7 – <3 years), group C included those in the
early childhood period from 3 years to 6 years of age (3 – <6 years), and group D
included those in the late childhood period from 6 to 12 years of age (6 – 12 year).
Samples where relative expression values were 1.5 times outside the 25th and 75th
percentiles were considered outliers and removed prior to statistical analysis. Less than
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Figure 2-2. Representative Real Time PCR Amplification Plot for Target Human
Genes.
Ct, cycle threshold; ∆Rn, emission intensity of the reporter minus the threshold Rn.
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15% of the total sample size was considered outliers for each of the targeted gene
expression. Statistical comparison of mean values for target gene expression between
each group was performed using one-way ANOVA with Bonferroni post-hoc test.
Target gene mRNA expression =

Initial amount of t arg et gene
Initial amount of reference gene

Mean ± standard deviation (SD) values for all relative target gene mRNA
expression were calculated for each age group. Asterisks represent statistically
significant differences (p < 0.05) in mean normalized mRNA expression between group
A and the other age group(s). Correlation between the nuclear receptors themselves and
between the nuclear receptors and MDR1/P-gp and MRP2 was determined by linear
regression analysis. The goodness of fit is denoted by the r2 value and significance
determined by the F test for simple linear regression.
P-gp and MRP2 protein expression was detected by immunoblotting and quantified
by band density. The GAPDH bands were included in order to verify equal amount of
protein loading for each sample. Additionally, GAPDH was used as a reference gene in
order to normalize the P-gp and MRP2 protein density. Each blot was verified as within
the linear range by comparing the 1 minute versus the 3 minute exposure. Linearity
curves constructed from known protein concentrations of control P-gp and MRP2
membranes were also performed in order to verify linearity. Non-detectable sample
values were assigned a zero value and all data points were included in the analysis.
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Results
mRNA Expression of MDR1/P-gp and MRP2 in Human Pediatric Liver Samples
Using real time RT-PCR methodology, we were able to detect both ABC
transporters MDR1 and MRP2 in all human pediatric liver samples. Limited MDR1 and
MRP2 mRNA expression was detected in the youngest age group – A (age range from
0.25 - < 0.7 years old; approximately 4 – 8 months) but markedly increased with
maturation (Figure 2-3). Ontogenic mRNA expression of MDR1 and MRP2 was
statistically significant between the youngest age group A and age group B.
Interestingly, age group B MDR1 and MRP2 mRNA expression level surpassed not only
age group A, but also age groups C and D. For MDR1, age groups A, B, and C were
36%, 157%, and 129% relative to age group D, respectively. In a similar pattern, MRP2
gene expression for age groups A, B, and C were 25%, 127%, 118% relative to age group
D. Though relative expression values in age groups C and D for MDR1 and MRP2 were
higher than those in age group A, it was not statistically significant. There appeared to be
high variability in expression of the ABC transporters regardless of age group.
Coefficient of variation for MDR1 ranged from 44 – 77% while those of MRP2 ranged
from 13 – 72%. Normalized mRNA expression values for individual human pediatric
liver samples for MDR1 and MRP2 within each age group are represented in scatterplots.
The values are also summarized in box and whiskers plots within each age group (Figure
2-4 and Figure 2-5).
mRNA Expression of Orphan Nuclear Receptors (NRs) in Human Pediatric Liver
Samples
Nuclear receptors PXR, CAR, FXR, and HNF4α mRNA expression overall showed
very little age associated development as compared to the ontogenic expression exhibited
by MDR1 and MRP2 (Figure 2-6 to Figure 2-9). However, a general trend was observed
for PXR, FXR, and HNF4α where expression levels were lowest in the youngest age
group but increased to maximal levels by age groups B or C, and eventually decreased by
age group D. CAR expression appeared considerably different than the other nuclear
receptors. Expression level for CAR was actually highest in the youngest age group and
gradually decreased with an increase in age. Of all the nuclear receptors, FXR mRNA
expression in the youngest age group A was the only group which exhibited significantly
a lower expression value than the other age groups.
In accordance with a recently published study [77], we were able to confirm the coexpression between the mRNA expression of PXR, CAR, and HNF4α (Figure 2-10).
Specifically, in human pediatric liver samples, HNF4α was positively correlated with
PXR (r2 = 0.16, p = 0.002) and CAR (r2 = 0.14, p = 0.003). While the literature supports
evidence of HNF4α regulation of PXR and CAR, there have been no reports of HNF4α
associated regulation of FXR. We were able to provide evidence for the lack of
correlation between HNF4α and FXR (r2 = 0.008, p = 0.49).
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Figure 2-3. Normalized Target Gene Expression.
Relative target gene expression levels in human pediatric liver samples are represented as
percentages (mean ± SEM) of those observed for the oldest age group D. Asterisks
represent significant differences (p < 0.05) in mean normalized target gene expression
between age group A versus the other age group(s). Y, years.
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MDR1 mRNA/Cyclophin mRNA in pediatric liver
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Figure 2-4. mRNA Expression of MDR1/P-gp in Human Pediatric Liver Samples.
Upper panel, box and whisker plot of cyclophilin A normalized MDR1 mRNA
expression. Boxes represent 25th and 75th percentiles and horizontal bars represent 10th
and 90th percentiles while open circles represent outliers. Mean ± SD for each age group
are reported. Lower panel, scatterplot of cyclophilin A normalized MDR1 mRNA
expression versus age. X-axis is on a discontinuous scale ranging from 0 – 8 months and
> 8 months – 12 years.
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MRP2 mRNA/Cyclophilin mRNA in pediatric liver
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Figure 2-5. mRNA Expression of MRP2 in Human Pediatric Liver Samples.
Upper panel, box and whisker plot of cyclophilin A normalized MRP2 mRNA
expression. Boxes represent 25th and 75th percentiles and horizontal bars represent 10th
and 90th percentiles while open circles represent outliers. Mean ± SD for each age group
are reported. Lower panel, Scatterplot of cyclophilin A normalized MRP2 mRNA
expression versus age. X-axis is on a discontinuous scale ranging from 0 – 8 months and
> 8 months – 12 years.
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PXR mRNA/Cyclophilin mRNA in pediatric liver
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Figure 2-6. mRNA Expression of PXR in Human Pediatric Liver Samples.
Upper panel, scatterplot representation of cyclophilin A normalized PXR mRNA
expression for individual liver samples vs. Age group. Lower panel, box and whiskers
plot of cyclophilin A normalized PXR mRNA expression in each age group. Boxes
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles,
and circles represent outliers. Values indicate mean ± SD excluding outliers.

33

CAR mRNA/Cyclophilin mRNA in pediatric liver
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Figure 2-7. mRNA Expression of CAR in Human Pediatric Liver Samples.
Upper panel, scatterplot representation of cyclophilin A normalized CAR mRNA
expression for individual liver samples vs. Age group. Lower panel, box and whiskers
plot of cyclophilin A normalized CAR mRNA expression in each age group. Boxes
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles,
and circles represent outliers. Values indicate mean ± SD excluding outliers.
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FXR mRNA/Cyclophilin mRNA in pediatric liver
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Figure 2-8. mRNA Expression of FXR in Human Pediatric Liver Samples.
Upper panel, scatterplot representation of cyclophilin A normalized FXR mRNA
expression for individual liver samples vs. Age group. Lower panel, box and whiskers
plot of cyclophilin A normalized FXR mRNA expression in each age group. Boxes
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles,
and circles represent outliers. Values indicate mean ± SD excluding outliers. Asterisks
indicate significant differences in mean target gene expression between age group A and
the other age group(s) indicated.
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HNF4α mRNA/Cyclophilin mRNA in pediatric liver
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Figure 2-9. mRNA Expression of HNF4α in Human Pediatric Liver Samples.
Upper panel, scatterplot representation of cyclophilin A normalized HNF4α mRNA
expression for individual liver samples vs. Age group. Lower panel, box and whiskers
plot of cyclophilin A normalized HNF4α mRNA expression in each age group. Boxes
represent 25th and 75th percentiles, horizontal bars represent 10th and 90th percentiles,
and circles represent outliers. Values indicate mean ± SD excluding outliers.
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Figure 2-10. HNF4α Correlations in Human Pediatric Liver Samples.
Correlations between normalized target mRNA expression for nuclear receptors PXR,
CAR, and FXR versus normalized HNF4α mRNA levels. X-axis represents normalized
HNF4α mRNA expression levels. Y-axis is split into 3 different panels each representing
normalized PXR, CAR, or FXR mRNA expression values. Correlation between HNF4α
and the corresponding nuclear receptor is indicated by the r2 value. P-values are reported
as well.
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We also explored the correlations between the nuclear receptors and the drug
transporters (Figure 2-11 to Figure 2-13). Expression of PXR was positively correlation
with MDR1 (r2 = 0.20, p = 0.001) and to a lesser extent with MRP2 (r2 = 0.07, p = 0.04).
In contrast, expression of CAR did not correlate with the expression of either drug
transporters. FXR expression in the human pediatric liver positively correlated with both
MDR1 (r2 = 0.19, p = 0.001) and MRP2 (r2 = 0.13, p = 0.01) mRNA expression.
Protein Expression of MDR1 and MRP2
Western blot analysis of human pediatric liver samples revealed a single band at
~170 kDa, ~190 kDa, and ~40 kDa corresponding to P-gp, MRP2, and GAPDH,
respectively (Figure 2-14). The successful detection of P-gp and MRP2 was verified by
their positive controls. Normalized protein expression was lowest in age group A as
compared to the other age groups for both P-gp and MRP2 (Figure 2-15). Age group B
had the highest measured P-gp and MRP2 protein expression as compared to all other age
groups. After reaching the maximal expression level in age group B, both P-gp and
MRP2 protein levels gradually decreased with increase in age. Variability in protein
expression for both transporters was high regardless of age group. Coefficient of
variation for P-gp ranged from 59 – 67% while those of MRP2 ranged from 46 – 90%.
P-gp was non-detectable for 2% of the samples in age group A, but 100% was detected in
all other age groups (Figure 2-15). MRP2 was non-detectable in 50% of the samples in
age group A, but detectable in 87%, 94% and 97% in age group B, C, and D (Figure
2-16). There were no significant differences in P-gp protein expression between the
various age groups. However for MRP2, protein expression was significantly higher in
age groups B (p < 0.001), C (p < 0.01), and D (p < 0.05) than age group A.
Discussion
This study described the ontogeny of ABC transporters MDR1, MRP2, and of
orphan nuclear receptors PXR, CAR, FXR, and HNF4α in human pediatric liver samples
using real time RT-PCR and Western immunoblotting techniques. While there have been
some published reports on the age associated expression of Mdr1/P-gp, Mrp2, as well as
selected nuclear receptors in animal models, there lacked sufficient evidence for the same
association in human transporter development. One of the main barriers in conducting
such studies in humans has been simply the lack of availability of human pediatric
samples. Furthermore, archived samples in human tissue banks have often originated
from donors diagnosed with disease (i.e. cancer), tissue pathologies, or exposure to drug
therapy which may alter the expression of drug transporters or nuclear factors. Also, a
majority of samples stored in tissue banks originated from post-mortem donors.
Unfortunately, RNA from post-mortem samples often has been unusable due to their
rapid degradation by RNAses prior to cryopreservation. In the present study, we were
fortunate to obtain a large number of pediatric liver tissues preserved from living donors.
As such, we were able to extract intact RNA as well as membrane proteins from these
liver biopsies. However, in order to gather more information regarding transporter
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Figure 2-11. PXR Correlations to MDR1 and MRP2.
Correlation between normalized target mRNA expression for MDR1 and MRP2 mRNA
expression versus normalized PXR mRNA levels.
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Figure 2-12. CAR correlations to MDR1 and MRP2.
Correlation between normalized target mRNA expression for MDR1 and MRP2 mRNA
expression versus normalized CAR mRNA levels.
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Figure 2-13. FXR Correlations to MDR1 and MRP2.
Correlation between normalized target mRNA expression for MDR1 and MRP2 mRNA
expression versus normalized FXR mRNA levels.
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Figure 2-14. Representative Western Immunoblots of MDR1/P-gp and MRP2 in
Human Pediatric Liver Samples.
Each column is a representative blot from each of the four age groups. Human MDR1/
P-gp and MRP2 control membranes were included in each blot as a reference.
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Figure 2-15. MDR1/P-gp Protein Expression in Human Pediatric Liver Samples.
Upper panel, Box and whisker plot of normalized P-gp protein expression. Boxes
represent 25th and 75th percentiles and horizontal bars represent 10th and 90th
percentiles while open circles represent outliers. Mean ± SD for each age group are also
shown as well as the percent of sample not detected within each age group (%ND).
Lower panel, Scatterplot of normalized P-gp protein expression versus age. X-axis is on
a discontinuous scale ranging from 0 – 8 months and >8 months – 12 years.
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Figure 2-16. MRP2 Protein Expression in Human Pediatric Liver Samples.
Upper panel, Box and whisker plot of normalized MRP2 protein expression. Boxes
represent 25th and 75th percentiles and horizontal bars represent 10th and 90th
percentiles while open circles represent outliers. Bold print in text and asterisks within
graph represent significant differences between the age group A versus the other
indicated age groups (p < 0.05). Mean ± SD for each age group are also shown as well as
the percent of sample not detected within each age group (%ND). Lower panel,
Scatterplot of normalized MRP2 protein expression versus age. X-axis is on a
discontinuous scale ranging from 0 – 8 months and >8 months – 12 years.
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ontogeny in the early weeks after birth, we added postmortem liver samples to our
original mRNA data set. Due to RNA degradation in the postmortem samples, we were
only able to measure protein and not mRNA content in those samples.
For MDR1/P-gp gene expression, we were able to identify significantly lower
mRNA expression between the early infant (before 8 months) and early childhood period
(8 months – 3 years). Our MDR1/P-gp protein expression in the pediatric liver samples,
however, was not significantly different across the various age groups in our subset of
protein samples. The discordance in the relative expression of MDR1/P-gp mRNA and
P-glycoprotein has been described in various cancer cell lines [81, 82]. This raises the
possibility of post-transcriptional regulation of MDR1 as a potential source of variation
for mRNA and protein expression in human pediatric liver samples. van Kalken et al.
reports a strong expression of P-gp in early human fetal liver development [65]. Our
protein data extends their findings and supports high P-gp expression in the human
pediatric liver from the neonatal throughout late childhood ages. The crucial protective
role P-gp plays in preventing intracellular endogenous or exogenous substrate
accumulation would support its strong presence at birth especially in organs with
excretory functions such as the liver and kidneys.
Similar to MDR1/P-gp, MRP2 mRNA expression was significantly lower in the
early infant months as compared to the early childhood period. Furthermore, we were
able to characterize the same relationship for MRP2 protein samples whereby the early
infant period (birth – 8 months) exhibited the lowest MRP2 protein expression compared
to all the other developmental periods. The high occurrence of jaundice or
hyperbilirubinemia often observed in premature infants and newborns may be partially
attributed to the immature development of MRP2 at birth since MRP2 is the primary
hepatic canalicular transporter that mediates various organic anions as well as sulfated or
glucuronidated bile salts and bilirubin. Our findings provide direct physiologic evidence
of immature MRP2 expression in the early infant period of development. Aside from
bilirubin, immaturity of MRP2 expression at birth could also potentially impact the
elimination of drug molecules that are substrates of MRP2. Therefore, in the pediatric
population, especially for newborns, medications with high biliary excretion may exhibit
altered pharmacokinetic properties and thus, may necessitate special pediatric dosing or
monitoring.
The nuclear receptors PXR, CAR, and FXR are all involved in the co-regulation of
drug metabolizing enzymes and drug transporters through activation of the response
elements of their target genes. Furthermore, there is a considerable level of overlap in the
inducers of both PXR and CAR. This ‘cross-talk’ or ‘cross-regulation’ between PXR and
CAR provides redundancy in the regulation of their target gene expression such as the coexpression of CYP3A4 and P-gp [56]. Though PXR, CAR, and FXR all have roles in
human bile acid and lipid metabolism, FXR appears to be the main nuclear receptor
charged with direct bile acid and cholesterol homeostasis. Transcriptional targets of FXR
include ileal bile acid binding protein (IBABP), bile salt export pump (BSEP), sodium
taurocholate contransporting peptide (NTCP), cholesterol 7-α hydroxylase (CYP7A1),
and MRP2 – all metabolizing enzymes or transporters directly involved in bile acid
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absorption, synthesis, or secretion [57, 71, 83]. In the present study, both the mean and
median mRNA expression values for PXR and FXR were lowest in the youngest age
group and increased over time. Our results support an ontogenically regulated expression
of PXR and FXR and appears to coincide with another study with limited human fetal
liver samples which shows lower FXR mRNA expression as compared to adult liver
samples [67]. However, unlike the PXR and FXR gene expression, CAR mRNA
expression remained relatively constant throughout the different age groups. CAR has
been reported to be constitutively expressed and localized in the cytoplasm of
hepatocytes. Unlike PXR and FXR, CAR must translocate into the cell nucleus before
activation of its target gene response elements [84]. Our results support a constitutive
expression of CAR which does not appear to fluctuate with age.
Apart from the developmental patterns in nuclear receptor expression, we also
described a positive correlation between HNF4α, PXR, and CAR mRNA expression.
The results agree with a previous study linking the co-expression between the nuclear
receptors [77] and also support other findings that HNF4α is an important master
regulator in coordinating the nuclear receptor mediated response to xenobiotics
specifically in the liver [76]. HNF4α, as a critical determinant of PXR and CAR
induction of CYP3A, may also play a significant role in the upregulation of P-gp given
that CYP3A and P-gp are often co-expressed and co-induced. To date, there are no
studies which suggest the regulation of FXR through HNF4α. This is echoed by the lack
of correlation between HNF4α and FXR in the current study.
Besides exploring the relationships between the nuclear receptors themselves, we
wished to also examine the correlations between the nuclear receptors PXR, CAR, and
FXR and the drug transporters MDR1/P-gp and MRP2. Significant correlations were
detected between PXR and FXR along with MDR1/P-gp and MRP2. In particular, the
relationship between PXR and MDR1/P-gp was strongly correlated (p = 0.0001) while
PXR and MRP2 was moderated associated (p = 0.04). This corresponds with the role
PXR plays in the coordinated regulation of drug metabolizing enzymes and drug
transporters. Conversely, CAR expression lacked correlation with either P-gp or MRP2.
This was somewhat surprising given that CAR, similar to PXR, also serves as a crucial
regulator of Phase I through Phase III drug disposition mechanisms. Our findings
support CAR as a constitutively expressed nuclear receptor whose activation of target
gene receptors potentially occurs through a different mechanism as compared to PXR. In
particular, the lack of direct correlation between CAR and drug transporter expression
might be due to a multifaceted process whereby other co-regulators may be involved in
CAR activation. In contrast to CAR, both MDR1/P-gp and MRP2 were highly correlated
with FXR expression. Our findings support the role of FXR in maintaining bile acid
homeostasis through its regulation of MDR1/P-gp as well as MRP2.
The aims of the current study were to characterize the age associated development
for ABC transporters MDR1/P-gp and MRP2 as well as nuclear receptors PXR, CAR,
FXR, and HNF4α in human pediatric livers. Our relatively large sample size included
liver tissue from both living as well as deceased donors. The liver samples from the
living donors were analyzed for both mRNA and protein expression studies while the
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liver samples from the deceased donors were acquired in order to better characterize the
ABC transporter protein expression especially in the newborn and infant periods. Our
results revealed an age-associated expression whereby the youngest age group exhibited
the lowest gene transcript level for MDR1/P-gp and MRP2 mRNA expression. Protein
expression data, however, indicated only a significant age dependent expression of
MRP2. The dissociation in mRNA and protein expression in our MDR1/P-gp samples
might be the result of post-transcriptional regulation which would need to be
substantiated with further research.
For the nuclear receptors, we were able to establish a positive correlation between
HNF4α along with PXR and CAR, but not for FXR. This appeared consistent with
published literature which supports HNF4α as a master-regulator of PXR and CAR. We
also explored the relationships between the nuclear receptors and drug transporters in
order to ascribe the potential regulatory control of the nuclear receptors on the
developmental patterns observed for MDR1/P-gp and MRP2. We identified positive
correlations between the nuclear receptors PXR and FXR with MDR1/P-gp and MRP2.
However, we were not able to detect correlations between CAR and the ABC
transporters. The correlations between PXR and ABC transporters seem consistent with
the role of PXR as a major transcriptional regulator of drug metabolizing enzymes and
drug transporters. The role FXR serves as a main regulator of bile acid homeostasis in
the liver also supports its associations with MDR1/P-gp and MRP2. The lack of
correlations between CAR and the ABC transporters suggest the possibility of additional
co-regulators that may be involved in the activation of MDR1/P-gp and MRP2.
The immaturity of human hepatic MRP2 in the early postnatal period described in
this study provides a partial explanation for the high incidence of hyperbilirubinemia in
newborns. Besides endogenous substrates such as bilirubin and bile acids, the role of
MRP2 as a major hepatic transporter of organic anions might also result in altered
clearance of such pharmacological agents, particularly in newborns. An important
extension of the current study will be to examine the variability in the pharmacokinetic
parameters of medications with high biliary clearance in a system with impaired or
deficient MRP2 expression.
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CHAPTER 3. AGE-ASSOCIATED EXPRESSION OF HEPATIC ABC DRUG
TRANSPORTERS AND NUCLEAR RECEPTORS IN RAT LIVER

Introduction
Similar to humans, rodents also express the ABC drug transporters MDR1/P-gp and
MRP2. Unlike humans, however, rodent multidrug resistance protein MDR1/P-gp is
encoded by two isoforms – Mdr1a (as referred to as Mdr3) and Mdr1b (Mdr1) [85-88].
Mouse Mdr1a is highly expressed in the intestinal epithelium and at the blood–brain and
blood–testis barriers, whereas Mdr1b is highly expressed in the adrenal gland, pregnant
uterus, and ovaries. In addition, both genes are substantially expressed in many other
tissues, including liver, kidney, lung, heart, and spleen [89, 90]. While tissue distribution
of Mdr1a/1b varies widely, these two highly homologous gene isoforms appear to be coexpressed in the mouse liver and contribute equally in the overall hepatic MDR1/P-gp
function. The sequence homology between rodent and human Mdr1-type genes is
virtually complete [90-92]. Furthermore, rodent P-gp transport of various
chemotherapeutic agents, endogenous glucocorticoids, as well as various exogenous drug
substrates are analogous to the function of human P-gp [88, 90, 93].
Although it shares less than 20% amino acid identity with Mdr1/P-gp, Mrp2
localization is very similar to Mdr1/P-gp including the intestines, liver, and kidney [41,
94]. Similar to human MRP2 in both localization and function, rodent Mrp2 also plays a
central role in the hepatobiliary excretion of various endogenous and exogenous
substrates including bile acids, bilirubin, various organic anions, as wells as conjugates of
glucuronates, glutathiones, or sulfates [95, 96]. Mutations in the MRP2 gene can cause
an autosomal recessive disorder which results in hereditary hyperbilirubinemia. The
human form of the mutation causes Dubin-Johnson syndrome, while in rats, a similar
mutation results in the EHBR (Esai hyperbillirubinemic rat) and the TR-strain of MRP2deficient rats [97].
Ontogenic regulation of ABC transporters Mdr1a/1b (P-gp) and Mrp2 has
previously been explored in humans as detailed in Chapter 2. Due to the limited
availability of human pediatric liver biopsies, however, the use of animal tissues from
various ages is often used as an alternative to gain knowledge about the ontogeny of drug
disposition processes and has provided great insight into the developmental process of
these drug transporters. While there is a general consensus from the currently published
animal studies on the fact that transporter expression is age-associated, some of the
reported results are equivocal. According to Rosati [63], gene expression of Mdr1a/1b
increases around postnatal day 21 in the rat liver and reaches maximum expression by
postnatal day 60. However, western blots of mouse liver for P-gp indicates an abundance
of P-gp at birth and throughout maturation into adulthood [62]. An age associated
expression pattern has also been described for Mrp2 in the rat liver whereby Mrp2 gene
expression increase significantly between postnatal days 6 – 12 and approaches a
maximal expression value by day 30 [61, 63]. Similar to the studies by Rosati [63] and
Gao [61], we have reported an ontogenic process in MRP2 mRNA and protein expression
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in human pediatric liver samples of varying ages. We also reported a significant age
associated mRNA expression for MDR1/P-gp in the same pediatric liver samples.
As mentioned in Chapter 2, orphan nuclear receptors include a gene superfamily of
transcriptional factors that regulate the expression of its target genes, many of which
include drug metabolizing enzymes and drug transporters [70]. Paving the molecular
regulatory pathway for their target gene expression, nuclear receptors may partly
contribute to the interindividual and ontogenic variability observed in drug transporter
expression. Nuclear receptors that target the expression of MDR1/P-gp and MRP2
include PXR, CAR, and FXR [57, 58, 71, 72], while HNF4α appears to be a master
regulator of PXR and CAR [76]. Many of the ligands which activate transcription factors
within the nuclear receptors are drug substrates frequently used in pediatric
pharmacotherapy including rifampin, phenobarbital, clotrimazole, and dexamethasone
[98]. Even endogenous substrates such as bile acids and their precursors can modulate
the downstream expression of drug transporters through activation or inhibition of
nuclear receptors [72].
Only two studies have so far investigated the ontogenic expression of nuclear
receptors [71, 77]. No study to date has examined the developmental patterns of nuclear
receptors and their correlation to drug transporter development. From our human
pediatric liver samples, we were able to measure the mRNA expression of four different
nuclear receptors involved in the regulation of MDR1/P-gp and MRP2 including PXR,
CAR, FXR, and HNF4α. We were able to show a positive correlation between HNF4α,
a master regulator of other nuclear receptor, and PXR and CAR expression. Along the
same lines, we were also able to identify positive correlations between the nuclear
receptors PXR and FXR to both ABC transporters.
Knowledge regarding the developmental expression of ABC transporters as well
their regulation by nuclear receptors can provide crucial information regarding
differences observed between pediatric and adult pharmacotherapy. In the present study,
we characterized the ontogeny of rat liver Mdr1a/1b and Mrp2 by performing relative
quantification for both mRNA and protein expression. These data are generated to
supplement our previous findings on the ontogeny of MDR1/P-gp and MRP2 in human
livers. The rat was chosen as model animal as it is the most established and wellcharacterized model species for drug disposition, metabolism and toxicology. To
describe their developmental pattern of Mdr1a/1b and Mrp2 in more detail, we expanded
upon the previous published studies by including more age groups ranging from postnatal
day 0, 3, 7, 14, 21, 28, and adult rats (considered by sexual maturity by postnatal day 60)
[99]. In addition, we also characterized the mRNA expression of regulatory
transcriptional factors Pxr, Car, Fxr, and Hnf4α for the same rat liver samples. We then
compared the mRNA expression between the four nuclear receptors in order to
characterize their co-regulation. Lastly, we investigated the correlations between the
mRNA expression of the nuclear receptors and the drug transporters Mdr1a, Mdr1b, and
Mrp2.
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Materials and Methods
Sample Acquisition
Pregnant Sprague-Dawley (SD), 28 day-old, and adult aged (60 day-old) rats were
acquired from Harland (Indianapolis, IN) and housed at 25ºC on a 12-hour light/dark
cycle. All animals were housed in standard laboratory cages and had free access to food
and water throughout the entire study. Pups delivered by the pregnant rats were raised to
pre-determined ages including newborn, 3, 7, 14, and 21 days of age. After reaching the
appropriate pre-determined age, six rats were selected at random and anesthetized with
isoflurane . Liver biopsies were dissected out and immediately frozen in liquid nitrogen.
All rats were sacrificed by creating a pneumothorax. All frozen liver samples were
stored at -70ºC until further processing. The experimental protocol was approved by the
Animal Care and Use Committee (ACUC) of the University of Tennessee Health Science
Center. All procedures related to the sample acquisition were performed by Dr. Wenhui
Zhang [100].
Total RNA Isolation and cDNA Synthesis
Total RNA from the rat livers was isolated using RNAgents® Total RNA Isolation
Kit (Promega, Madison, WI) according to manufacturer’s protocol. Briefly,
approximately 0.3 g of frozen liver was added to 600 µL of denaturing solution and
homogenized using a handheld homogenizer for approximately 15 seconds or until no
fragments of tissue were visible. Next, 60 µL of 2M sodium acetate followed by 600 µL
of phenol:chloroform:isoamyl alcohol was added to each homogenate, mixed thoroughly,
and then vigorously shaken for 10 seconds. After chilling the entire mixture on ice for 15
minutes, the vials were centrifuged at 10,000 g for 20 minutes at 4ºC. The top aqueous
phase was transferred to a fresh centrifuge tube, and an equal amount of ice-cold
isopropanol was then added in order to precipitate total RNA from the aqueous phase.
Total RNA was precipitated for 30 minutes in a -20ºC freezer followed by a second
centrifugation step at 10,000 g for 15 minutes. The resulting RNA pellet was then
washed with ice-cold 75% ethanol and re-pelleted by centrifugation. After discarding the
ethanol, the RNA pellet was air dried and finally each RNA pellet was dissolved in 10 –
50 µL of nuclease-free water depending on the pellet size. RNA concentrations were
estimated by measuring its ultraviolet absorbance (A) at 260 nm and 280 nm, whereby 1
absorbance unit (A260) = 40 µg of RNA/mL. The purity of the RNA isolate was
estimated by comparing the ratio for A260/A280. RNA samples were considered pure with
only minor protein contamination if the calculated ratio of A260/A280 was between 1.7 and
2.0. Only samples with high purity were further processed for first strand cDNA
synthesis.
First strand cDNA synthesis was performed by using the Superscript III kit
(Invitrogen, Carlsbad, CA) on an Eppendorf® Mastercycler™ (Westbury, NY). Oligo dT
was used as the primer for mRNA first-strand synthesis. An aliquot totaling 1 µg of total
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RNA was mixed with 1 µL of 10 mM dNTP mix and 1 µL of 0.5 µg/µL Oligo(dT)12-18.
The total mixture was then brought to 10 µL with the addition of DEPC-treated water.
The mixture was incubated at 65ºC for 5 minutes on a heating block, then immediately
placed on ice for at least 1 minute. A mixture of 2 µL of 10x RT buffer, 4 µL of 25 mM
MgCl2, 2 µL of 0.1 M DTT, 1 µL of RNAseOUT™ recombinant RNase inhibitor, and 1
µL of SuperScript™ III reverse transcriptase was added to each reaction vial. The entire
mixture was then incubated for 50ºC for 50 minutes and the reaction was terminated by
increasing the temperature to 85ºC for 5 minutes. Residual RNA was removed by adding
1 uL of RNAse H and incubating at 37ºC for 20 minutes. The resulting cDNA was stored
at -20ºC until real-time RT-PCR was performed.
Real Time PCR
Primers pairs and TaqMan probes for Mdr1a, Mdr1b, Mrp2, Pxr, Car, Fxr, and
Hnf4α (TaqMan® Assay-on-Demand™ Products) as well as the constitutively expressed
housekeeping gene Cyclophilin A (TaqMan® Pre-Developed Assay Reagents for Gene
Expression) were obtained from Applied Biosystems (Foster City, CA). All targeted
ABC transporter and nuclear receptor probes were labeled with 6-carboxyfluorescein
(FAM)-dye while the cyclophilin probe was labeled with VIC™-dye. All of the probes
were quenched by 6-carboxytetramethylrohodamine (TAMRA) on the 3’ end. Target
gene probe sequences are summarized in Table 3-1. In a 96-well reaction plate, 2.5 µL
of 20X TaqMan Probe, 22.5 µL of cDNA created from the rat liver, and 25 µL of 2X
TaqMan Universal PCR Master Mix were added. The reaction was performed in
duplicate for each sample. Real time RT-PCR was performed using the ABI Prism®
Sequence Detection System 7000 (Applied Biosystems, Foster City, CA) using the
default PCR thermal cycling conditions consisting of an initial TaqMan Universal PCR
Master Mix activation at 50°C for 2 min, followed by an initial denaturation step at 95°C
for 10 min, then 40 cycles of 95°C for 15 sec and 60°C for 1 min.
Relative mRNA quantification was achieved through the standard curve or Ct (cycle
threshold for target or endogenous control gene amplification) slope method. The
average Ct value was calculated from replicates of each sample using the ABI Sequence
Detection System SDS software (Applied Biosystems, Foster City, CA). Mdr1a, Mdr1b,
Mrp2, Pxr, Car, Fxr, Hnf4a, and cyclophilin A standard curves were prepared from serial
dilutions of cDNA from a standard adult rat sample. Dilutions included 1, 2, 4, 10, and
20 fold initial cDNA concentration (C0). A plot of Ct, the point at which the
amplification plot cross the threshold cycle value, vs C0 was then constructed (Figure
3-1) as described by the assay manufacturer [78]. The threshold value was predetermined
as 3 times the average baseline cycle value calculated from cycles 6 – 15. The log
concentration of the unknown samples was then calculated by linear regression from the
standard curve. The absolute concentration was then determined by taking its antilog
value. The expression level of each target gene was then calculated relative to the
reference gene, cyclophilin A.
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Table 3-1.

Primer Sequence for Target Gene-Specific 5’-(FAM)-Labeled TaqMan® Assay-on-Demand™ Rat Probes.
Gene
Alternative
Symbol name
Probe 5'-3'

NCBI Gene
Reference

Target
Exons

Abcb1a
Abcb1
Abcc2
Nr1i2
Nr1i3
Nr1h4
Hnf4α

NM_133401.1
NM_012623.2
NM_012833.1
NM_052980.1
NM_022941.2
NM_021745.1
NM_022180.1

20
5
14
8
7
3
3

Mdr1a
Mdr1b
Mrp2
Pxr
Car
Fxr
Hnf4α

TGAAAGGGGCTACAGGGTCTAGGCT
ACATGGCCATGTACGCCTACTATTA
TCACCATCCAGGGATCCACAGCCTA
CTATCCTGCACACAGGTTCCTGTTC
TCAAGACTCCAAAGTCGGTTTCTGT
GGGCTGCAAAGGTTTCTTCCGAAGA
CATGAAGAAAGAAGCCGTCCAAAAT
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mdr1a
mdr1b
mrp2
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fxr
hnf4a

40

35

Ct

30

25

20

15
-2.5

-2.0

-1.5

-1.0

-0.5

0.0

Log Co

Figure 3-1. Calibration Curve for Mdr1a, Mdr1b, Mrp2, Pxr, Car, Fxr, and Hnf4α.
Serial dilutions of cDNA created from a reference sample taken from an adult rat. All
targeted genes calibration curves have slopes of approximately -3.3, indicating an
amplification efficiency of close to 1 within the linear range.
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Tissue Membrane Protein Isolation
Membrane proteins for all rat liver samples were extracted through the
Calbiochem® ProteoExtract® Native Membrane Protein Extraction Kit (M-PEK)
according to the manufacturer protocol. Briefly, approximately 50 mg of liver tissue was
homogenized in 2 mLs of Extraction Buffer I and incubated for 10 minutes at 4°C under
gentle agitation on a rotary shaker. The homogenate was centrifuged for 15 minutes at
16,000 g and 4°C. The supernatant was discarded and the pellet resuspended in 1 mL of
Extraction Buffer II. The cell pellet containing membrane and cytosolic proteins was
then incubated for 30 minutes at 4°C again under gentle agitation on a rotary shaker. The
cell suspension was centrifuged a second time at 16,000 x g and 4 °C for 15 minutes.
The resulting supernatant enriched in membrane proteins was then transferred to a fresh
tube and stored in aliquots at -70°C until further processing.
Protein quantification was determined by the method of Bradford Assay [79] using
bovine serum albumin (BSA; Sigma-Aldrich) as the standard. Using a 96 well plate,
stock BSA solution (0.2 mg/mL) was diluted to a final concentration ranging from 0 – 30
µg/mL with dH20 in the standard wells. In the sample wells, 1 µL of membrane protein
from each pediatric liver sample was dilute in 199 µl of dH20. 50 µL of Protein Assay
Dye Reagent Concentrate (Bio-Rad) was added to each well and mixed thoroughly. All
protein standards and unknown samples were measured in triplicates. The plate was
incubated for 5 minutes at room temperature and the protein absorbance was read on a
microplate reader at 595 nm. A standard curve using the standard BSA absorbance (A)
versus concentration was constructed. All unknown protein concentrations were
subsequently calculated using the standard curve. 20 µg of membrane protein from each
liver sample was used for protein quantification.
SDS-PAGE/Western Blotting
To 20 µg of rat liver membrane protein, 2.5 mL of NuPAGE® LDS Sample
Preparation Buffer (Invitrogen, Carlsbad, CA) was added. The samples were
fractionated via SDS-PAGE using NuPAGE® 4 – 12 % Bis-Tris Gel with 1X NuPAGE®
MOPS Running buffer at 200 V for 1 hour. On each gel, we also included a MultiMark®
Multi-Colored Protein Standard molecular weight ladder (Invitrogen, Carlsbad, CA).
Human P-gp membrane preparation (Human PGP membranes) and MRP2 membrane
preparations (Human MRP2 membranes) purchased from BD Gentest™ (Woburn, MA)
were also included on each gel as positive controls. The separated proteins were
transferred overnight onto a Invitrolon™ PVDF 0.2 um membrane at 30 V using
NuPAGE® 1X Transfer Buffer with 10% methanol.
Nonspecific binding sites on the PVDF membrane were blocked using 5% nonfat
dried milk in phosphate buffered saline (PBS; pH 7.4) with 0.1% Tween for 1 hour at
room temperature. The membrane was then incubated with a primary monoclonal
antibody to P-gp (C219) (Alexis Biochemicals, San Diego, CA) diluted 1:100 fold,
MRP2 (M2III-6) (Alexis Biochemical, San Diego, CA) diluted 1:200 fold, or GAPDH
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(Sigma-Aldrich, St. Louis, MO) diluted 1:10000 fold in 5% nonfat dried milk in PBS
with 0.1 % Tween (PBST) for 2 hours at room temperature. After discarding the primary
antibody, the membrane was washed 3 times with PBST each time for 5 minutes. The
membrane was then incubated for 1 hour with the secondary antibody, HRP-conjugated
Anti-Mouse IgG (Cell Signaling Technology, Danvers, MA), diluted in 5% nonfat dried
milk in PBST either 1:5000 fold when probing P-gp and MRP2, or 1:10000 fold when
probing for GAPDH. After 3 – 5 minute washings with PBST, the blots were then
incubated with enhanced chemiluminescence ECL plus™ (GE Healthcare, Piscataway,
NJ) for 5 minutes, then developed on Kodak® Biomax™ XAR autoradiography film
(Sigma-Aldrich, St. Louis, MO) after 1 minute and 3 minute exposure times. Protein
band density was quantified using ImageJ [80] after digitizing the image using a flatbed
scanner.
Statistical Analysis
All statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL).
During real time PCR, an amplification plot, reported as ∆Rn vs. Ct, was generated for
each sample (Figure 3-2). ∆Rn represented the fluorescence emission intensity of the
reporter minus the threshold Rn. Threshold Rn was determined from the pre-set baseline.
The Ct value for each sample was then used to back calculate an initial input amount by
using the equation derived from the calibration curve regression line. All data were backlog transformed in order to achieve homoscedasticity, and target gene values were then
normalized to the endogenous control cyclophilin A. The rat liver samples were divided
into seven age groups (0, 3, 7, 14, 21, 28 day-old, and adult). Statistical comparison of
mean value for target gene expression between each group was performed using one-way
ANOVA with Bonferroni post-hoc test.
Target gene mRNA expression =

Initial amount of t arg et gene
Initial amount of reference gene

Mean ± standard deviation (SD) values for all relative target gene mRNA
expression were calculated for each rat age group. Statistically significant results (p <
0.05) are denoted with asterisks. Correlation between the nuclear receptors themselves
and between the nuclear receptors and the ABC transporters was determined. The
goodness of fit is denoted by the r2 value and significance determined by the F test for
simple linear regression.
P-gp and Mrp2 protein expression was detected by immunoblotting and quantified
by band density. The Gapdh bands were included in order to verify equal amount of
protein loading for each sample. Additionally, Gapdh was used as a reference gene in
order to normalize the P-gp and Mrp2 protein density. Each blot was verified as within
the linear range by comparing the 1 minute versus the 3 minute exposure. Samples where
relative expression values were 1.5 times outside the 25th and 75th percentiles were
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Figure 3-2. Sample Real Time PCR Amplification Plot for Target Rat Genes.
∆Rn represents the fluorescence emission intensity of the reporter minus the threshold R.
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considered outliers and removed prior to analysis. Again, statistical analysis was
performed using one-way ANOVA followed by Bonferroni post-hoc test. Statistically
significant results (p < 0.05) are denoted with asterisks.
Results
mRNA Expression of Mdr1a, Mdr1b, and Mrp2 in Rat Liver Samples
Using real time RT-PCR methodology, we were able to detect ABC transporters
Mdr1a, Mdr1b and Mrp2 in all rat liver samples. Compared to the adult rat group, the
relative Mdr1a expression in 0, 3, 7, 14, 21, and 28 day-old age groups were 10.6%,
7.0%, 23.6%, 26.1%, 96.5%, and 157.5%, respectively (Figure 3-3). Limited Mdr1a
mRNA expression was detected for 0 and 3 days old rats followed by a gradual increase
in the 7 and 14 days old age groups (Figure 3-4). Mdr1a mRNA expression dramatically
increased between 14 and 21 days, and eventually reached maximal expression level by
28 days. Significant differences in mean Mdr1a mRNA expression values were detected
for 0, 3 and 7 day-old rat groups as compared to the 28 day-old group.
Low expression values were measured for Mdr1b in the early age groups 0, 3, 7,
throughout 14 days-old rats which then increased to a maximal expression value by 28
days of age (Figure 3-5). Mdr1b mRNA expression then increased between 14 and 21
days and reached a peak in 28 days of age. Mdr1b expression values were 39.2%, 11.3%,
49.6%, 52.1%, 76.2%, and 169.5% of the adult group for groups 0, 3, 7, 14, 21, and 28
days-old (Figure 3-3). Though mean values suggested an age-associated gene expression
for Mdr1b, statistical analysis revealed no significant differences between any of the age
groups.
Similar to Mdr1a and Mdr1b, rat liver Mrp2 expression remained low in the
younger age groups from 0 days throughout 21 days. However, Mrp2 expression
dramatically increased between 21 day- and 28 day-old rats and eventually reached
maximal values by adult age (Figure 3-6). When compared to adult aged rats, expression
values were 10.7%, 11.9%, 22.1%, 12.4%, 26.1%, and 75.4% in the 0, 3, 7, 14, 21, and
28 day-old rats, respectively (Figure 3-3). Statistical analysis revealed significant
differences between age groups 0, 3, 7, 14, and 21 days-old versus the adult rats. There
was no difference detected for Mrp2 mRNA expression between 28 day-old and adult
rats.
mRNA Expression of Orphan Nuclear Receptors (NRs) in Rat Liver Samples
Similar to the rat hepatic ABC transporters, the nuclear receptors Pxr, Car, and
Fxr all exhibited age-associated expression. Pxr gene expression for newborn rats was
approximately 49% of adult Pxr expression but decreased gradually to between 25% 35% between 3 through 21 days of age before increasing back to approximately 56% of
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Figure 3-3. Ontogeny of Mdr1a, Mdr1b, and Mrp2 Expression in Rat Liver Samples.
Values are normalized target gene expression relative to the adult liver group. Asterisks
(*) represents significant differences (p < 0.05) between the various age groups as
compared to the adult group.
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Figure 3-4. Ontogeny of Normalized Mdr1a mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Mdr1a mRNA expression of individual rats by
each age group. Lower panel, bar graph presenting mean ± standard deviation from six
rat liver samples in each age group. Mdr1a, mdr1-type isoform a of the rat multidrug
resistance gene P-glycoprotein.
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Figure 3-5. Ontogeny of Normalized Mdr1b mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Mdr1b mRNA expression of individual rats by
each age group. Lower panel, bar graph presenting mean ± standard deviation from six
rat liver samples in each age group. Mdr1b, mdr1-type isoform b of the rat multidrug
resistance gene P-glycoprotein.
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Figure 3-6. Ontogeny of Normalized Mrp2 mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Mrp2 mRNA expression of individual rats by
each age group. Lower panel, bar graph presenting mean ± standard deviation from six
rat liver samples in each age group. Mrp2, rat multidrug resistance-associated protein 2.
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adult values by 28 days of age. Car gene expression followed a similar developmental
pattern as Pxr. Newborn rat liver Car mRNA expression was approximately 20 – 25% of
adult expression in the first 3 weeks of life, but dramatically increased to approximately
59% by 28 days of age. Fxr mRNA expression was initially 30% of adult at birth through
3 days of age. Expression then spiked to 40% in 7 days of age before decreasing to 26%
in 14 day-old rats. By 21 days, Fxr gene expression had climbed to 45%, and by 28 days
it had reached 65% of adult Fxr expression. Age associated mRNA expression for Hnf4α
in the same rat livers, however, was slightly different then the other nuclear factors.
Newborn rat liver Hnf4α was only 50% of adult values at birth, but decreased to 26% by
3 days of age, and eventually increased back to 56% by 7 days of age before dropping
back to 25% by 14 days of age. Hnf4α in rat livers then increased from 69% to 93% of
adult expression by 21 and 28 days of age, respectively (Figure 3-7).
Statistical comparisons revealed significance in Pxr expression between all age
groups ranging from newborn through 28 days-old rats as compared to adult rats (Figure
3-8). The same was true for Car where significant differences were detected in mRNA
expression between newborn through 21 day-old rat livers versus adult rat livers (Figure
3-9). Fxr mRNA expression in newborns through 21 day-old rat livers were significantly
different than adult liver expression as well (Figure 3-10). Unlike all the other nuclear
receptors, Hnf4α did not exhibit any significant age associated expression between any of
the age groups examined (Figure 3-11).
In order to investigate the coordinated regulation between nuclear receptors, we
also compared the normalized mRNA expression of Pxr, Car, and Fxr versus Hnf4α. We
were able to detect a positive correlation between all three nuclear receptors and Hnf4α
in the rat liver samples. Pxr was positively correlated with Hnf4α (r2 = 0.22, p = 0.003)
and Car (r2 = 0.28, p < 0.001). Fxr also exhibited a positive correlation to Hnf4α with (r2
= 0.59, p < 0.001). Next, we compared the correlations between the rat hepatic nuclear
receptors and the ABC transporters (Figure 3-12 to Figure 3-15). mRNA expression of
all three nuclear receptors (Pxr, Car, and Fxr) were positively correlated with those of the
ABC transporters (Mdr1a, Mdr1b, and Mrp2). Expression of Pxr was positively
correlated with Mdr1a (r2 = 0.28, p < 0.001), Mdr1b (r2 = 0.32, p < 0.001), and Mrp2 (r2
= 0.29, p < 0.001). Similar, but weaker correlations were observed for Car and Mdr1a (r2
= 0.22, p < 0.01), Mdr1b (r2 = 0.23, p < 0.01), and Mrp2 (r2 = 0.26, p < 0.01). Much
stronger correlations were detected between Fxr and Mdr1a (r2 = 0.44, p < 0.01), Mdr1b
(r2 = 0.34, p < 0.01), and Mrp2 (r2 = 0.83, p < 0.01).
Protein Expression of Mdr1/P-gp and Mrp2 in Rat Liver Samples
We were successful in quantifying Mdr1/P-gp and Mrp2 protein expression for rat
liver samples ranging from newborns throughout adults. For Mdr1/P-gp, relative protein
expression was highest in the 28 days-old group followed by the 14 and 21 day-old
groups. The lowest Mdr1/P-gp protein expression occurred in the 0, 3, and 7 day-old rat
livers at 25% and 46% of adult protein levels, respectively (Figure 3-16). Statistically, 0,
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Figure 3-7. Ontogeny of Nuclear Receptors Pxr, Car, Fxr, and Hnf4α in Rat Liver
Samples.
Values are normalized target gene expression relative to the adult liver group. Asterisk
(*) represents a significant difference as compared to the adult group (p < 0.05). Pxr,
pregnane X receptor; Car, constitutive androstane receptor; Fxr, farnesoid X receptor;
Hnf4α, hepatic nuclear factor 4α.
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Figure 3-8. Ontogeny of Normalized Pxr mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Pxr mRNA expression of individual rats by each
age group. Lower panel, bar graph presenting mean ± standard deviation from six rat
liver samples in each age group. Pxr, pregnane X receptor.
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Figure 3-9. Ontogeny of Normalized Car mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Car mRNA expression of individual rats by each
age group. Lower panel, bar graph presenting mean ± standard deviation from six rat
liver samples in each age group. Car, constitutive androstane receptor.
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Figure 3-10. Ontogeny of Normalized Fxr mRNA Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Fxr mRNA expression of individual rats by each
age group. Lower panel, bar graph presenting mean ± standard deviation from six rat
liver samples in each age group. Fxr, farnesoid X receptor.
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Upper panel. scatterplot of normalized Hnf4α mRNA expression of individual rats by
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rat liver samples in each age group. Hnf4α, hepatic nuclear factor 4α.
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Figure 3-12. Hnf4α Correlation Analysis in Rat Liver Samples.
Correlation between normalized target mRNA expression for nuclear receptors Pxr, Car,
and Fxr versus normalized Hnf4α (Hnf4a) mRNA levels. X-axis represents normalized
Hnf4α mRNA expression levels. Y-axis is split into 3 different panels each representing
normalized Pxr, Car, or Fxr mRNA expression values. Correlation between Hnf4α and
the corresponding nuclear receptor is indicated by the r2 value. A p-value for each
correlation is reported as well.

68

Target ABC transporter normalized mRNA expression

Mrp2 by Pxr

2.0

0.5

r 2=0.29, p<0.001

Mdr1b by Pxr

1.8

0.8
r 2=0.32, p<0.001

Mdr1a by Pxr

5.0

2.0
r 2=0.28, p<0.001

1

3

5

7

9

Pxr nomalized mRNA expression

Figure 3-13. Pxr Correlations to Mdr1a, Mdr1b, and Mrp2.
Correlation between normalized target mRNA expression for Pxr versus normalized
target ABC transporter levels. X-axis represents normalized Pxr mRNA expression
levels. Y-axis is split into 3 different panels each representing normalized Mdr1a,
Mdr1b, or Mrp2 mRNA expression values. Correlation between Pxr and the
corresponding ABC transporter is indicated by the r2 value. A p-value for each
correlation is reported as well.

69

Target ABC transporter normalized mRNA expression

Mrp2 by Car
r 2=0.26, p=0.001

2.0

0.5
Mdr1b by Car

1.8

0.8
r 2=0.23, p=0.004

Mdr1a by Car

5.0

2.0
r 2=0.22, p=0.004

1

3

5

7

9

Car normalized mRNA expression

Figure 3-14. Car Correlations to Mdr1a, Mdr1b, and Mrp2.
Correlation between normalized target mRNA expression for Pxr versus normalized
target ABC transporter levels. X-axis represents normalized Car mRNA expression
levels. Y-axis is split into 3 different panels each representing normalized Mdr1a,
Mdr1b, or Mrp2 mRNA expression values. Correlation between Car and the
corresponding ABC transporter is indicated by the r2 value. A p-value for each
correlation is reported as well.
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Figure 3-15. Fxr Correlations to Mdr1a, Mdr1b, and Mrp2.
Correlation between normalized target mRNA expression for Pxr versus normalized
target ABC transporter levels. X-axis represents normalized Fxr mRNA expression
levels. Y-axis is split into 3 different panels each representing normalized Mdr1a,
Mdr1b, or Mrp2 mRNA expression values. Correlation between Fxr and the
corresponding ABC transporter is indicated by the r2 value. A p-value for each
correlation is reported as well.
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Figure 3-16. Ontogeny of Mdr1a and Mrp2 Protein Expression in Rat Liver Samples.
Values are normalized target gene expression relative to the highest expression group.
Asterisks (*) represent significant differences (p < 0.05) between the various age groups
as compared to the adult group.
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3, and 7 day-old rat liver samples all had significantly lower Mdr1/P-gp expression (p <
0.05) than the 28 day-old rat livers (Figure 3-17).
Mrp2 relative protein expression in the rat liver remained low in the first weeks of
life and eventually reached maximal value by adulthood. 0 and 3 day-old livers
expressed 14% and 15% of adult liver Mrp2, while 7 day-old rat livers expressed almost
10% of adult Mrp2 content. Mrp2 protein expression increased gradually to
approximately 60% of adult expression between 14 and 28 days of age (Figure 3-16).
Significant differences (p < 0.05) were detected between the 0, 3, and 7 day-old versus
adult liver groups (Figure 3-18).
Protein expression for both Mdr1 and Mrp2 overall matched those from the relative
mRNA expression in the same liver samples. In general, Mdr1/P-gp protein and mRNA
expression were low in the 0, 3, and 7 day-old groups and increased to a maximal level
later in during postnatal development. Likewise, Mrp2 values for both mRNA and
protein expression remained low early in life and gradually increased to maximal values
throughout postnatal maturation. For Mdr1/P-gp protein expression, 14 day-old rat liver
samples did not exhibit a significant difference as compared to 28 day samples as was for
the Mdr1a mRNA expression data. Similarly for Mrp2, 14 and 21 day-old liver protein
expression was not significantly different from the adult samples as suggested by the
Mrp2 mRNA expression data.
Discussion
In the current study, we examined the ontogeny of ABC transporters Mdr1a,
Mdr1b, and Mrp2 as well as nuclear receptors Pxr, Fxr, Car, and Hnf4α in rats during
seven specific time points throughout maturation ranging from newborn to adult. For the
transporters, we performed both real-time RT-PCR as well as Western immunoblots in
order to semi-quantitate their mRNA and protein expression. For the nuclear receptors,
we characterized their mRNA expression using real-time RT-PCR. We were able to
describe an ontogenic process in rat liver Mdr1/P-gp as well as Mrp2 mRNA and protein
expression. An age-associated expression was also described for the nuclear receptors
Pxr, Car, and Fxr.
Overall, mRNA expression for Mdr1a, Mdr1b, and Mrp2 were low throughout the
first three weeks of life. For Mdr1a and Mdr1b, normalized mRNA expression increased
from 21 day-olds liver samples to a maximal expression level by 28 days of age before
declining to adult levels. The Mdr1a results were similar to those reported by Rosati [63]
where mRNA levels were less than 50% of 60 days-old rats from birth until
approximately 12 days-old in the rat liver. While the Mdr1b mRNA expression pattern
was similar to that obtained by Rosati [63], we could not detect significant differences
between the age groups. Mrp2 expression in the rat liver increased gradually from 0
days-old through 21 days of age before reaching 75% of adult expression values by 28

73

Normalized Mdr1/P-gp protein quantity

0.6

0.5

0.4

0.3

0.2

0.1

0.0
0 Days

3 Days

7 Days

*

*

*

0 Days

3 Days

7 Days

14 Days 21 Days 28 Days

Adult

14 Days 21 Days 28 Days

Adult

Normalized Mdr1/P-gp protein quantity

0.6

0.5

0.4

0.3

0.2

0.1

0.0

Figure 3-17. Ontogeny of Normalized Mdr1/P-gp Protein Expression in Rat Liver
Samples.
Upper panel. scatterplot of normalized Mdr1/P-gp protein expression of individual rats
by each age group. Lower panel, bar graph presenting mean ± standard deviation from
six rat liver samples in each age group. Asterisks (*) represents a significant difference (p
< 0.05) compared to the 28 day-old group. Underneath the mean ± standard deviation bar
graph is a representative western immunoblot of two Mdr1/P-gp samples from each
corresponding age group. Mdr1, multidrug resistance 1 gene/P-glycoprotein.
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Figure 3-18. Ontogeny of Normalized Mrp2 Protein Expression in Rat Liver Samples.
Upper panel. scatterplot of normalized Mrp2 protein expression of individual rats by
each age group. Lower panel, bar graph presenting mean ± standard deviation from six
rat liver samples in each age group. Asterisks (*) represents a significant difference (p <
0.05) compared to the adult group. Underneath the mean ± standard deviation bar graph
is a representative western immunoblot of two Mrp2 samples from each corresponding
age group Mrp2, multidrug resistance-associated protein 2.
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days of age. This pattern was consistent with the results of Rosati [63], where adult rat
liver Mrp2 expression was significantly greater than that of rats less than one week old.
Similar findings were reported by Gao [61], where Mrp2 mRNA expression in rat livers
from birth throughout 20 days of age fluctuated between 25 – 84% of adult values.
Zinchuk [101] also reported less than 50% of adult Mrp2 mRNA expression in those rat
livers less than one week of age.
Protein expression for Mdr1/P-gp in general matched those detected for mRNA
expression in our study. Mdr1/P-gp protein levels remained low throughout postnatal
maturation but increased dramatically between 14 days of age and adulthood. This
observation, however, was in contrast to a report by Mahmood [62], who stated that
Mdr1/P-gp protein levels were greater than 100% in the newborn, 7 day-, and 21 day-old
mouse liver as compared to adult mouse liver.
Similar to the Mdr1/P-gp results, Mrp2 protein expression in the rat livers also
mimicked their mRNA expression pattern. Both Mrp2 mRNA and protein expression
were less than 60% of adult values during the first 14 postnatal days, but increased to a
maximal level by adulthood. The only divergence between protein and mRNA
expression was that 14 day-old rat livers exhibited higher protein content then the mRNA
levels. Again, the developmental pattern was in agreement with those reported for rat
Mrp2 protein by Rosati [63], Gao [61], and Zinchuk [101]. Rosati [63] detected Mrp2
proteins in 15 day-old rats through immunoblotting while Gao [61], through
immunostaining of rat livers, was able to demonstrate positive canalicular
immunofluorescence comparable to those of adult rat livers in postnatal day 12 rats.
Regulators of Mdr1/P-gp and Mrp2 include nuclear receptors Pxr, Car, and Fxr [57,
58, 71, 72], while Hnf4α functions as a master regulator of Pxr and Car [76]. Given our
observation of the age dependency in Mdr1/P-gp and Mrp2 expression during rat liver
maturation, we also investigated the ontogenic expression of nuclear receptors as a
potential regulatory mechanism for the transporter expression. We were able to detect
significant differences in nuclear receptor expression for Pxr, Car, and Fxr throughout the
early postnatal period versus adulthood. Specifically, we described a developmental
pattern for Pxr and Car whereby rat livers from 0 to 21 postnatal days initially exhibited a
high transcript level at birth but gradually declined to 25% and 19% of adult levels by 21
days of age. However, by 28 days of age, both rat liver Pxr and Car expression
dramatically increased to those near adult levels. Unlike Pxr and Car, Fxr expression in
the rat livers followed a more gradual increase throughout maturation. Fxr mRNA
expression started from approximately 30% of adult levels at birth and gradually rose to
65% of adult levels by postnatal week 4. Our results were similar to previously published
results from Balasubramaniyan [71] and Huang [102] and further support the regulatory
role of nuclear receptors in age associated transporter expression. Balasubramaniyan [71]
provided evidence of limited Pxr and Fxr expression in rats less than four week of age as
compared to adult rats while Huang [102] reported that in mouse livers, expression of Car
mRNA was significantly lower in the first week of life as compared to adult mice.
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Nuclear receptors are considered crucial regulatory elements for the coordinated
expression of drug metabolizing enzymes and drug transporters, specifically those in the
family of cytochrome P450 of enzymes and the ABC family of transporters. As such, we
wished to determine whether the ontogeny observed in ABC transporters in our rat livers
could be partially explained by its regulation through the nuclear receptors. As
previously mentioned, HNF4α forms a higher level of regulation for drug metabolism and
transport by acting as a master regulator of nuclear receptors PXR and CAR [76]. We
were able to describe a positive correlation between Hnf4α, Pxr, Car, and Fxr mRNA
expression. Although our correlation cannot establish a direct causal relationship in
Hnf4α regulation of Pxr, Car, and Fxr, the data suggests a possible common pathway in
the maturational regulation of these nuclear receptors. Aside from the nuclear receptors
themselves, we also reported a positive correlation between Pxr, Car, and Fxr with the
ABC transporters. In particular, Fxr was highly correlated with Mrp2 expression in the
rat livers (r2 = 0.83, p < 0.0001). This suggests that regulation of hepatic Mrp2
expression occurs mainly through Fxr with minimal co-regulation by other nuclear
receptors.
The ontogeny of the ABC transporters and the nuclear receptors from our rat liver
samples all indicated an increase in their expression to levels comparable to adult rats
between 14 days and 28 days of age. This might be due to changes in environmental and
xenobiotic exposures during this phase of development. Specifically, rat wean from
breast milk at postnatal day 21 [99]. An increase in nuclear receptor expression and
subsequent drug transporter expression might be due to changes in dietary exposures of
these rats.
In conclusion, the findings in the current study further characterized the postnatal
ontogeny of Mdr1/P-gp and Mrp2 during liver development in the rat. Specifically,
Mdr1/P-gp and Mrp2 expression are incomplete early in the postnatal period but increase
throughout maturation. As regulatory agents of ABC transporter expression, we also
characterized the age-associated expression of nuclear receptors Pxr, Car, Fxr, and
Hnf4α. Again, we observed low expression of nuclear receptors a birth that increased to
adult values with maturation. Furthermore, we described positive correlations between
the expressions of the nuclear receptors and the ABC transporters. An important
extension of the current work will be to characterize whether changes in the expression
Mdr1/P-gp and Mrp2 during normal pediatric development can translate into clinically
significant difference in the elimination medications used in pediatric pharmacotherapy.

77

CHAPTER 4. THE EFFECT OF MRP2 DEFICIENCY ON THE IN VIVO
PHARMACOKINETICS OF CEFTRIAXONE IN RATS

Introduction
The human multi-drug resistance proteins (MRPs) consist of a family of ATPbinding cassette (ABC) transporters that mediate the unidirectional transport of various
organic anions as well as lipophilic substances conjugated to glutathiones, glucuronates,
or sulfates. MRP2 (ABCC2) has been recognized as a major transporter of bilirubin and
drug substrates as well as their conjugates into the bile. Thus, for drugs with
considerable biliary excretion, changes in MRP2 expression may translate into profound
differences in their pharmacokinetic profile and subsequent therapeutic efficacy. MRP2
has been associated with the biliary excretion of several therapeutic agents and its
metabolites used in pediatric pharmacotherapy including various antibiotics,
chemotherapeutic agents, and HIV protease inhibitors [103]. Specifically, MRP2 has
been implicated in the biliary excretion of several therapeutic agents and its metabolites
used in pediatric pharmacotherapy, including irinotecan, saquinavir, ritonavir, indinavir
and ceftriaxone [104, 105]. In humans, a deficiency in MRP2 occurs in patients with
Dubin-Johnson syndrome. Clinically, Dubin-Johnson syndrome manifests in chronic
conjugated hyperbilirubinemia as well as impaired conjugated organic anion transport
[106]. Mrp2 deficiency also occurs naturally in the TR-/Abcc2 strain of Wistar rats
rendering them as a widely used animal model for the study of Mrp2 function in drug
disposition [97].
As reported in the Chapters 2 and 3, MRP2 mRNA and protein expression in
humans and rats are limited in the early periods of development and increase with
maturation. Immaturity of MRP2-mediated drug transport throughout the body,
including decreased MRP2-mediated hepatic biliary excretion, may be a source of
deviation in drug pharmacokinetic properties between newborns and infants as compared
to adults.
We chose the third-generation cephalosporin antibiotic ceftriaxone (Rocephin®) as
model drug to study the effect of ontogeny on MRP2-mediated elimination processes.
Ceftriaxone is a broad spectrum cephalosporin antibiotic commonly used in the pediatric
population for ear infections, respiratory tract infections, as well as meningitis. In
contrast to the aforementioned MRP2 substrates, ceftriaxone is primarily eliminated by
renal and biliary excretion (33-67%) and does not appear to be metabolized to a relevant
extent [50]. Additionally, ceftriaxone is excreted into the bile as an unconjugated drug
[49, 104, 107]. Thus, studies on the effect of MRP2 ontogeny on ceftriaxone
pharmacokinetics (PK) are not be obscured by concurrent developmental processes in
Phase I or Phase II drug metabolizing enzymes, making ceftriaxone an ideal model drug
to study the functional consequences of transporter maturation on in vivo
pharmacokinetics. Additionally, there are implications that impaired MRP2 activity may
play a role in adverse events associated with ceftriaxone used in neonates. While the
product label advises against administering ceftriaxone to hyperbilirubinemic neonates,
78

several clinical reports of ceftriaxone induced cholestasis and pseudolithiasis in neonates
and children exist in the literature [54, 108]. While little is known about the mechanism
which leads to the biliary sludge, particularly for the high risk pediatric population, data
implicates the reduced biliary excretion of ceftriaxone possibly due to an immature
MRP2 in the pediatric patients [97, 109]. This suggests that newborns, particularly
premature infants whose drug clearance mechanisms are still in development, may
particularly be at a higher risk for ceftriaxone induced hyperbilirubinemia and
cholestasis.
The aim of the present study was to evaluate possible variations in ceftriaxone
disposition due to a deficiency in Mrp2 mediated biliary excretion. To do so, the
pharmacokinetic parameters of ceftriaxone were determined in an animal model using
wild-type and Mrp2-deficient (TR-) rats. The TR- rat was used as a model for decreased
hepatic Mrp2 expression as observed in neonates and young infants. We quantified
hepatic Mrp2 mRNA and protein levels in the WT and TR- rats in order to assess the
contribution of Mrp2 to ceftriaxone kinetics. While the literature does not provide any
evidence of Mdr1/P-gp in the biliary excretion of ceftriaxone, there is, in general, a
certain shared degree of overlapping substrate specificity between Mdr1 and Mrp2 [103].
Therefore, we also needed to assess the potential role of P-gp in the biliary excretion of
ceftriaxone through relative quantification of mRNA and protein expression of Mdr1/Pgp in the TR- and WT rats. The results of this study ultimately provide information for a
better understanding of the potential for transporter mediated ceftriaxone toxicity in
pediatric pharmacotherapy and the effect of transporter maturation in general.
Materials and Methods
Pharmacokinetic Study
Eight-week old male Wistar (Hsd:WI, n = 7) and Mrp2 deficient TR- (HsdAmc:TRAbcc2, n = 6) rats were obtained from Harlan Inc. (Indianapolis, IN). All animals were
catheterized in the external jugular vein by the vendor. Catheters were exteriorized
between the shoulder blades to ensure the catheter remained in place over the sampling
interval. Patency of the catheter was maintained by flushing the catheter daily with saline
and heparinized glycerin solution (500 U/ml) as per vendor protocol. All animals were
housed in individual standard laboratory cages on a 12 hour light-dark cycle and had
access to food and water ad lilbitum. The experimental protocol was approved by the
Animal Care and Use Committee (ACUC) of the University of Tennessee Health Science
Center.
All animals were allowed to recover from surgery for at least two days before
initiation of the PK study. On the first day of the PK study, the animals were given a
single tail vein injection of ceftriaxone 100 mg/kg reconstituted in saline for injection.
The rats were kept in plastic metabolic cages throughout the duration of the study. Blood
samples were collected at predose, and 5, 15, 30, 60, 90, 120, 180, 240, and 360 min after
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the dose. Approximately 200 µL of blood was drawn from the jugular vein catheter and
replaced immediately with an equal volume of saline solution. Blood samples were
stored in BD microvolume heparinized blood tubes and placed on ice. Plasma was
separated by centrifuging the samples for 2 minutes at 15,000 g at 4ºC. Cumulative 24
hour urine and feces were also collected. Plasma fractions, urine, and fecal samples were
stored at -20'C until analysis.
At the end of the study, all rats were anesthetized with carbon dioxide gas (CO2)
and sacrificed by cervical dislocation. Rat liver biopsies were dissected out and
immediately frozen in liquid nitrogen. All frozen liver samples were stored at -70ºC until
further processing.
Ceftriaxone Assay
Equipment
Ceftriaxone plasma concentrations were determined by high pressure liquid
chromatography (HPLC). The HPLC system consisted of a Shimadzu LC system
(Columbia, MD) which included a system controller (model SLC 10AVP), pump (model
LC-10AD), autosampler (Prominence SIL-20A), and UV detector (SPD-10AV) set at 270
nm and 0.01 absorbance unit. Data acquisition, processing, reporting, and system control
were performed with the LCsolution version 1.21 (Shimadzu, Columbia, MD) software.
Chromatographic peak separation was performed using the Gemini™ 5-µ C18 column
(150 x 4.6 mm) after passing through a Security Guard™ C18 4.0 x 2.0 mm guard column
(Phenomenex, Torrance, CA).
Chemicals and Reagents
Ceftriaxone sodium salt, cefuroxime sodium salt, and
hexadecyltrimethylammonium bromide (HDTA) were all purchased from Sigma-Aldrich
(St. Louis, MO). Potassium monophosphate (KHPO4), HPLC grade water and HPLC
grade acetonitrile were both obtained from Fisher Scientific (Fair Lawn, NJ).
The mobile phase consisted of 57-43% acetonitrile (v/v) in 10 mM K2HPO4 buffer,
pH 7.0, with 10 mM HDTA. A stock solution of 1 M K2HPO4 was made in distilled,
deionized water and later added to the mobile phase to make 10 mM K2HPO4. 10 g of
HDTA was weighed out and added to 1 L of mobile phase. The mobile phase was
degassed with a sonicator for 15 minutes. The flow rate was set at 1.0 mL/min.
Quantification
Quantification of ceftriaxone in rat plasma was modified from previously reported
methods [110-113]. Plasma samples (50 µl) were deproteinated with 450 µl of ice-cold
methanol (Fisher Scientific, Fair Lawn, NJ) along with 12.5 µl of a stock 100 µg/ml
cefuroxime solution as the internal standard. The sample was vortexed and placed on ice
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for 5 minutes followed by centrifugation at 2600 rpm for 5 minutes at 4ºC. 50 µl of the
plasma supernatant was used for HPLC analysis.
Rat urine samples were diluted ten fold by adding to 100 µl of urine 900 µl of
HPLC grade water along with 25 µl of the stock solution of cefuroxime 100 µg/ml. The
samples were then vortexed and centrifuged at 2600 rpm for 5 minutes at 4ºC. 25 µl of
the resulting supernatant was then used for HPLC analysis.
Rat fecal samples were first homogenized in 10 ml of distilled water. The samples
were then centrifuged at 2600 rpm for 5 minutes at 4ºC. 100 µl of the supernatant was
then diluted with 900 µl of HPLC grade water along with 25 µl of the internal standard
stock solution. The mixture was vortexed and 25 µl was used for HPLC analysis.
A standard curve was constructed by calculating the peak area ratio of ceftriaxone
and the internal standard cefuroxime for each of a series of calibration standards. The
concentration of calibration standards of ceftriaxone ranged from 10 through 500 µg/ml
for plasma, 10 through 800 µg/ml for urine, and 0.5 through 5 g/ml for feces. The peak
area ratio of the standards was plotted against their concentrations, and ceftriaxone
concentration from the experimental samples was calculated by linear regression from the
corresponding standard curves. All calibration curves were made prior to measurement
of the experiment samples with correlation values of at least 0.995. The lower limit of
quantification (LLOQ) was 10 µg/ml for plasma and urine and 500 µg/ml for fecal
samples. The accuracy of the assay was 13% and 17% at the LLOQ while the precision
was 15%..
Pharmacokinetic Analysis
The concentration-time data for ceftriaxone were analyzed by noncompartmental
pharmacokinetics analysis using WinNonlin Professional version 4.1 (Pharsight
Corporation; Mountain View, CA). Pharmacokinetic parameters calculated include
clearance (CL), volume of distribution at steady state (Vss), area under the curve (AUC),
elimination rate constant (k), half life (t1/2), percent dose of unchanged drug detected in
urine (% urine), and percent dose of unchanged drug detected in feces (% fecal).
Statistical analyses comparing each pharmacokinetic parameter between the TR- rats and
wild-type Wistar rats was performed using a two-tailed unpaired Student’s t-test through
SPSS version 14.0 (Chicago, IL).
mRNA and Protein Quantification for Mdr1a/1b and Mrp2
Mdr1a/1b and Mrp2 mRNA and protein levels from the frozen rat liver tissues were
analyzed using real time RT-PCR for mRNA quantification and Western immunoblotting
for protein quantification.
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Briefly, approximately 0.3 g of frozen liver tissue was added to 600 µl of
denaturing solution and homogenized using a handheld homogenizer for approximately
15 seconds or until no fragments of tissue were visible. Total RNA from the rat livers
was isolated using RNAgents® Total RNA Isolation Kit (Promega, Madison, WI)
according to the manufacturer’s protocol. First strand cDNA was synthesized from total
liver RNA using the SuperScript™ III First Strand cDNA Synthesis (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions. Real-time quantitative PCR was
performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems,
Foster City, CA) using primer pairs and TaqMan probes for rat Mdr1a, Mdr1b, and Mrp2
as well as the reference gene cyclophilin (see Chapter 3 for discussion on reference gene
selection). Relative mRNA quantification was achieved using a relative standard curve
methodology.
Protein levels of Mrp2 in the rat liver tissues were quantified through Western blot
analysis. Approximately 0.5 g of rat liver tissue was used for membrane protein isolation
through the use of Calbiochem® ProteoExtract® Native Membrane Protein Extraction Kit
(M-PEK) according to the manufacturer’s protocol. 20 µg of rat liver membrane protein
was fractionated using SDS-PAGE technique with NuPAGE® 4 – 12 % Bis-Tris Gel.
The separated proteins were then transferred overnight onto a Invitrolon™ PVDF 0.2 µm
membrane. Nonspecific binding sites on the PVDF membrane were blocked using 5%
nonfat dried milk in phosphate buffered saline (pH 7.4) with 0.1% Tween (PBST) for one
hour followed by primary monoclonal antibody incubation with P-gp (C219) (Alexis
Biochemicals, San Diego, CA) diluted 1:100 fold, MRP2 (M2III-6) (Alexis Biochemical,
San Diego, CA) diluted 1:200 fold, or GAPDH (Sigma-Aldrich, St. Louis, MO) diluted
1:10000 fold in 5% nonfat dried milk in PBST for two hours. After discarding the
primary antibody, the membrane was washed by three separate five minute washes with
PBST. The membrane was then incubated for one hour with the secondary antibody,
HRP-conjugated Anti-Mouse IgG (Cell Signaling Technology, Danvers, MA), diluted in
5% nonfat dried milk in PBST either 1:5000 fold when probing P-gp and MRP2, or
1:10000 fold when probing for GAPDH. After another three separate five minute
washings with PBST, the blots were then incubated with enhanced chemiluminescence
ECL plus™ (GE Healthcare, Piscataway, NJ) for 5 minutes, then developed on Kodak
Biomax XAR autoradiography film after 1 minute and 3 minute exposure times. Protein
band density was quantified using ImageJ (National Institutes of Health) after digitizing
the image using a flatbed scanner.
Results
Ceftriaxone Pharmacokinetics
The mean plasma concentration versus time profile following a single intravenous
injection of ceftriaxone 100 mg/kg in wild-type (WT) and Mrp2-deficient (TR-) Wistar
rats is depicted in Figure 4-1. The concentration-time curve appears monoexponential for
both groups. Mean pharmacokinetic parameters for ceftriaxone in wild-type and TR- rats
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are summarized in Table 4-1. The area under the curve (AUC) of ceftriaxone in TR- rats
was approximately 30% higher than in WT rats. This may be attributed to the 30%
decrease in clearance in the TR- rats. The elimination rate constant (k) decreased by
37%; consequently, terminal half-life (t1/2) of ceftriaxone in plasma was significantly
prolonged by approximately 34%. The volume of distribution at steady state (Vss) was
not significantly different between the two groups. The percent dose of ceftriaxone
eliminated in the urine was significantly increased from 25.5% to 64.5% in TR- rats as
compared to controls (p < 0.001). Conversely, the percent dose of ceftriaxone recovered
in feces was significantly higher in control rats than TR- rats (18.5% vs. 0%; p < 0.05).
Mdr1a, Mdr1b, and Mrp2 mRNA and Protein Quantification
We were able to detect Mdr1a, Mdr1b, and Mrp2 mRNA using real-time PCR in all
WT and TR- rat liver samples. Significant differences were detected for all three mean
target gene expression between WT and TR- rats. TR- rats livers exhibited
approximately three-fold higher expression of Mdr1a (p < 0.001) and Mdr1b (p < 0.05)
as compared to WT rat liver samples. As expected, TR- rat liver samples contained
limited levels of Mrp2 mRNA, which was significantly lower than WT Mrp2 expression
levels (p < 0.05) (Figure 4-2). Western blot analysis of WT and TR- rats revealed a
single band at ~170 kDa corresponding to Mdr1/P-gp as well as at ~190 kDa
corresponding to Mrp2 in the rat liver tissues (Figure 4-3). Mean normalized protein
expression levels were not significantly different for Mdr1/P-gp between WT and TRrats. However, mean Mrp2 protein expression level was significantly reduced for TR- rat
liver as compared to WT rat liver (p < 0.05) (Figure 4-4) Removal of outliers defined as
samples with relative expression values 1.5 times outside the 25th and 75th percentiles had
no influence on the statistical results.
Discussion
The present pharmacokinetic study on ceftriaxone disposition in WT vs. TR- rats
clearly demonstrates the significance of Mrp2 mediated biliary excretion of ceftriaxone.
Judging from the plasma concentration-time profile of a single intravenous administration
of ceftriaxone in WT and TR- rats, we observed a significantly lower elimination rate
constant (k) for TR- rats as compared to the WT rats. We could attribute the change in
elimination rate constant as an overall decrease in clearance in the TR- rats since there
were no changes in volume of distribution between the two groups. This translated into a
higher systemic exposure/AUC of ceftriaxone in the TR- rats. Since ceftriaxone is nearly
completely eliminated as unchanged drug by excretion into the bile and urine, we were
able to delineate the contribution of renal versus biliary elimination without any
confounding effects of drug metabolizing enzymes.
No detectable amounts of ceftriaxone (LLOQ of 500 µg/ml in feces) were detected
in the TR- fecal samples after 24 hours. However, approximately 19% of the original
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Table 4-1.

Mean ± SD Pharmacokinetic Parameters in WT versus TR- Rats.

k (h-1)
t1/2 (h)
Vss (L/kg)
CLT (L/h/kg)
CLr (L/h/kg)
AUCinf (mg*h/L)
% urine (24 h)
% fecal (24 h)
a

Wild-type

TR-

0.928 ± 0.24
0.788 ± 0.19
0.321 ± 0.11
0.279 ± 0.09
0.076 ± 0.05
396 ± 148
25.5 ± 12
18.5 ± 16

0.588 ± 0.06b
1.19 ± 0.12c
0.314 ± 0.05
0.189 ± 0.05a
0.123 ± 0.05b
570 ±182
64.5 ± 17c
0.0 ± 0.0a

p < 0.05; b p < 0.01; c p < 0.001
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Figure 4-2
WT versus TR- Rat Liver Mdr1a, Mdr1b, and Mrp2 mRNA Expression.
Bar graph presenting mean ± standard deviation for hepatic mRNA gene expression of
Mdr1a, Mdr1b and Mrp2 (normalized for cyclophilin (Cyc) expression) in WT vs. TRrats. Asterisks (*) represent a significant difference (*p < 0.05; **p < 0.001).
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Figure 4-3. Immunoblot of WT and TR- Rat Liver P-gp and Mrp2 Protein
Expression.
Representative Western blots of P-gp and Mrp2 in wild-type (WT) and Mrp2-deficient
rats (TR-). P-gp and Mrp2 control membranes were included in each blot as a reference.
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Figure 4-4. WT versus TR- Mdr1/P-gp and Mrp2 Protein Expression.
Upper panel: Scatterplot of normalized P-gp and Mrp2 protein expression of individual
WT and TR- rats. Lower panel: Bar graph presenting mean ± standard deviation for
normalized P-gp and Mrp2 mRNA gene expression in WT vs. TR- rats.
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dose of ceftriaxone was recovered in the 24 hour fecal samples of the WT rats. This
supports our hypothesis that biliary excretion of ceftriaxone is mediated through liver
Mrp2. This is further supported by the mRNA and protein quantification of Mdr1a/b and
Mrp2 in both the WT and TR- rats. Biliary excretion of ceftriaxone through Mdr1/P-gp
is improbable since expression of P-gp was detected in TR- rats yet no detectable amount
of ceftriaxone was recovered from the feces.
Our results showed an apparent increase in renal clearance of ceftriaxone in the TRrats as compared to the WT rats. This may indicate a potential compensatory mechanism
in the TR- rats for the overall clearance of ceftriaxone. Rat glomerular filtration rate has
been estimated at 0.312 L/h/kg [114]. The predicted filtration rate of ceftriaxone in WT
rats with a unbound fraction estimated at 5% would therefore be 0.0156 L/hr/kg [113].
Ceftriaxone renal elimination in both the WT and TR- rats appeared to undergo a net
filtration and secretion process since the excretion ratio exceeded one in both instances.
Previous reports have also demonstrated an increase in the urinary excretion of various
organic anions with Mrp2-deficient rats [115, 116]. This indicates a potential upregulation of other drug transporters in the kidney to compensate for the loss of Mrp2
function. Chen et al. [67] have recently provided evidence of increased Mrp4 expression
in the kidneys of TR- rats. Given that Mrp2 and Mrp4 share overlapping substrate
profiles as well as similar co-localization at the apical membrane of renal proximal
tubules, the increase in renal clearance may be attributed to the upregulation of renal
Mrp4 in the TR- rats. However, further experiments in TR- rats would be needed in
order to confirm the underlying mechanisms which contribute to the renal elimination of
ceftriaxone.
One other finding of interest was the significant elevation in mRNA expression
level of Mdr1a and Mdr1b in the TR- rats as compared to the WT rats. However, the
protein level of P-gp in the TR- rats was not significantly different from the WT rats.
The discordance in Mdr1a/b mRNA and P-gp protein expression suggests potential
regulatory mechanisms at the post-transcriptional level.
Mrp2 mediated biliary excretion has potentially important clinical implications for
pediatric pharmacotherapy. As concluded in the previous chapters, newborn and young
infants have decreased or immature expression of hepatic Mrp2 as compared to older
children and adults. For drugs with significant elimination through the bile, such as
ceftriaxone, competition for biliary excretion via Mrp2 especially in the early stages of
development may exacerbate or even cause clinical symptoms such as hyperbilirubinemia
or even cholestasis. Reduced MRP2 mediated biliary excretion may also translate to a
substantially decreased clearance and prolonged half-life of the affected medications in
neonates and infants with immature biliary excretion function, thereby increasing the
systemic exposure to these compounds. For drugs with a narrow therapeutic window,
decreased Mrp2 mediated biliary excretion may lead to toxic drug concentrations in
newborns and infants. Even for drugs which undergo Phase I and Phase II metabolism,
the impact of the ontogeny of Phase III drug transporters must be considered when
determining the pharmacokinetic profile of the drug or its metabolites. For example, for
a compound that is biotransformed into a glucuronidated or sulfated metabolite which is a
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substrate for Mrp2, the potential competition for Mrp2 mediated biliary elimination may
result in significant metabolite accumulation and subsequent reduced metabolic
conversion of the parent drug and/or undesirable side effects related to the increased
concentrations of parent drug or the metabolite.
The present study clearly defines the changes in pharmacokinetic parameters for
ceftriaxone in wild-type versus Mrp2-deficient TR- rats. We use this animal model to
illustrate the impact of low or deficient Mrp2 expression on drug elimination especially
during the early stages of pediatric development as profiled in the human liver samples of
newborns and infants investigated in Chapter 2. Pediatric clinical trials studying these
effects are often unfeasible due to limitations in cost, recruitment, biological sampling,
and ethical issues. The utility of mutant or knock-out animal models is invaluable in such
cases where human studies are not feasible. While inter-species differences must be
considered when extrapolating results from animal models to humans, an understanding
of the basic effects of drug transporters and lack of their functional activity on in vivo
drug pharmacokinetics nevertheless brings us a step closer to understanding and
explaining some of the variability and toxicity observed in pediatric pharmacotherapy.
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CHAPTER 5. SUMMARY

Advances in technology and understanding of systems biology have provided
tremendous strides towards improvements in modern human medicine. Unfortunately,
the business of drug development often overlooks the needs of the pediatric population
mainly due to cost issues as well as a lack of understanding of the dynamic changes
which occur in children especially in the early stages of their development. Therefore, as
more and more studies emerge on human organogenesis and physiology, it is the
responsibility of clinical pharmacologists to translate such knowledge into safe and
effective pharmacotherapy for all ages. In the current dissertation, we hypothesized that
there are age associated changes in drug transporter expression which can lead to
significant changes in pharmacokinetic parameters of drugs often used in pediatric
pharmacotherapy. We aimed at unraveling a piece of the childhood development puzzle
through characterization of the ontogeny of two major members in the ATP-binding
cassette (ABC) family of drug transporters – MDR1/P-gp and MRP2 in human samples.
In order to map out the ontogeny of these transporters in more detail, we also measured
their expression in rats from seven specific ages ranging from newborn to adult. In
addition, we sought to explain their potential developmental pattern by examining the
expression of their regulators in the superfamily of nuclear receptors – including PXR,
CAR, FXR, and HNF4α. Lastly, we demonstrated the potential clinical impact of
maturational changes in drug transporters on the pharmacokinetic properties of
ceftriaxone, a third generation cephalosporin antibiotic often used in the pediatric
population.
Our study in human pediatric liver samples revealed significantly lower MDR1/Pgp mRNA expression between the early infant (before 8 months) and older childhood
period. Our MDR1/P-gp protein expression in the pediatric liver samples, however, did
not support the results for MDR1 mRNA expression. P-gp protein level was not
significantly different across the various age groups in our subset of protein samples.
The discordance in the relative expression of MDR1/P-gp mRNA and P-glycoprotein has
been described in various cancer cell lines [81, 82]. This raises the possibility of posttranscriptional regulation of MDR1 as a potential source of variation for mRNA and
protein expression in human pediatric liver samples.
MRP2 mRNA and protein quantification in the human pediatric liver samples
revealed significant differences during ontogeny. Specifically, we demonstrated that
MRP2 expression is limited in the early infant period but increases dramatically to levels
comparable to childhood levels immediately prior to one year of age. Clinically,
newborns are often jaundiced in the early postnatal period. This is thought to partly be
due to the relatively immature hepatic metabolic pathways and hepatic transporter
mediated elimination of unconjugated bilirubin. MRP2 is the primary hepatic canalicular
transporter that mediates various organic anions as well as sulfated or glucuronidated bile
salts and bilirubin. We provide evidence that hepatic expression of MRP2 is immature at
birth, and therefore, drugs with high biliary excretion may exhibit altered
pharmacokinetic properties and should be administered with caution in newborns.
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Nuclear receptors belong to a family of transcriptional factor which regulate the
expression of their target genes, several of which include drug metabolizing enzymes and
transporters. In particular, several nuclear receptors including PXR, CAR, FXR, and
HNF4α have been identified as regulatory agents for ABC transporters including
MDR1/P-gp and MRP2. We quantified the expression of the nuclear receptors in order
to establish their regulatory role in the development of MDR1/P-gp and MRP2. Our
results revealed an interesting profile. PXR and FXR exhibited a lower expression level
in the early phase of development. However, CAR and HNF4α showed no differences
throughout the early postnatal through childhood ages. Though both PXR and FXR
expression was lower in the earlier age group, significant differences were only detected
for FXR. Physiogically, this makes plausible sense since FXR is often referred to as a
bile sensor capable of regulating the molecular processes which maintain bile acid
homeostasis. Immaturity of FXR expression at birth is supported by evidence that bile
acid synthesis and homeostasis appear to be postnatal ontogenic events as well.
Due to the limitations of conducting scientific research in humans, the use of
animal models has historically provided great insight into our understanding of human
development. As such, we wished to examine the ontogeny of Mdr1a/1b, Mrp2, Pxr,
Car, Fxr, and Hnf4α from rat liver samples in seven different postnatal ages in order to
compliment our human results with more selected spacing of age and sample numbers in
our rat samples. While the age at which maximal expression of these transporters and
nuclear receptors differed; in general, we observed a developmental pattern in the
expression of all the target genes. The protein levels for P-gp and Mrp2 also correlated
well with the mRNA expression data. Expression of Mdr1/P-gp and Mrp2 were limited
in the early periods of development, but gradually increased to maximal expression levels
at approximately 28 days of age. Results for the nuclear receptors Pxr, Car, and Fxr were
similar in that rat livers from 0 to 21 postnatal days initially exhibited less than 50% of
adult rat liver content but increased dramatically from 28 days of age to adulthood. A
similar pattern was observed for Hnf4α, though its mean relative expression appeared
highly variable within each age group. From the rat model, we concluded that expression
of Mdr1a/1b, Mrp2, Pxr, Car, and Fxr, in rat liver samples were significantly lower in the
early postnatal period as compared to the older age groups.
The results from the human and rat liver transporter ontogeny studies led us to our
next hypothesis that developmental changes in drug transporter expression could result in
significant changes in the pharmacokinetic parameters of drug substrates for these
transporters. We decided to test our hypothesis by comparing the pharmacokinetic
parameters of ceftriaxone, a third generation cephalosporin antibiotic, in wild-type (WT)
and a mutant strain of Mrp2-deficient (TR-) rats. We selected Mrp2-deficient rat as a
surrogate model to represent the immaturity of Mrp2 early on in development as was
evident from our rat and human liver samples. Ceftriaxone clearance was approximately
30% lower in the TR- group as compared to the WT group. Elimination half-life was
approximately 30% longer for the TR- group since there was no significant change in
volume at steady state between the two groups. There were no recoverable amounts of
ceftriaxone in the feces of TR- rats as compared with the 19% unchanged drug recovered
in the feces of the WT rats. Interestingly, there was almost a 40% increase in urinary
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excretion of ceftriaxone in the TR- indicating a potential compensatory mechanism for
clearance of the drug. mRNA and protein expression of Mdr1a/1b and Mrp2 confirmed a
deficiency of Mrp2 in the TR- rats as well as confirming the biliary excretion of
ceftriaxone by Mrp2.
We have successfully determined the age associated expression of ABC
transporters MDR1/Mdr1a/b and MRP2/Mrp2 in both human and rat liver samples.
Furthermore, we also examined developmental expression of various nuclear receptors
thought to be regulators of these drug transporters. Lastly, we demonstrated the changes
in pharmacokinetic properties of ceftriaxone in a Mrp2-deficient rat model. The results
of this study not only emphasize that children are not small adults, i.e. have distinctly
different drug disposition mechanisms, but also that empiric dosing of drugs based on
adult pharmacotherapy often used in the pediatric population may compromise the safety
and efficacy of these medications. The challenge in pediatric pharmacotherapy will lie in
the translation of our knowledge of the developmental pharmacology and biology during
childhood into rational and practical drug design as well as age-appropriate dosing
recommendations.
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